DNAs and proteins or peptides specific to bacteria of the species Neisseria meningitidis, processes for obtaining them and their biological uses

ABSTRACT

The DNA of the invention are characterised in that they concern the whole or part of genes, with their reading frame, to be found in  Neisseria meningitidis,  but not in  Neisseria gonorrhoeae,  or in  Neisseria lactamica  except the genes involved in the biosynthesis of the polysaccharide capsule, frp A, frp C, opc, por A, rotamase the sequence IC1106, IgA protease, pilline, pilC, transferrin binding proteins and opacity proteins. The invention also concerns the polypeptides corresponding to these DNA and the antibodies directed against these polypeptides. It is applicable in the prevention and the detection of meningococcus induced infections and meningitis.

[0001] The invention relates to DNAs and to proteins and peptides which are specific to bacteria of the species Neisseria meningitidis (abbreviated below to Nm), to the process for obtaining them and to their biological uses, in particular for the prevention and detection of meningococcal infections and meningitis.

[0002] It is known that Nm is one of the main agents of cerebrospinal meningitis.

[0003] Studies conducted in the United States have shown that 5 to 10% of the population are asymptomatic carriers of the Nm strain(s). The transmission factors of Nm are poorly known. For a proportion of persons infected, Nm penetrates the bloodstream, where it can cause meningococcaemia and/or progress to the cerebrospinal stream, to cause meningitis. Without fast antibiotic treatment, the infection can develop like lightning and become fatal.

[0004] Compared with other pathogens, Nm has the characteristic of being able to cross the haemato-encephalic barrier to colonize the meninges. The study of the pathogenicity of Nm is therefore important not only in the context of meningitis, but also in the context of any disease which affects the brain.

[0005] The benefit of having available tools specific to this species of bacteria for the uses envisaged above is therefore understood.

[0006] Genetically, Nm is very close to bacteria of the species Neisseria gonorrhoeae (abbreviated to Ng below) and of the species Neisseria lactamica (abbreviated to Nl below). However, their pathogenicity is very different.

[0007] Nm colonizes the nasopharynx, and then crosses the pharyngeal epithelium to invade the submucous space, thus being responsible for septicaemia and meningitis.

[0008] Ng is especially responsible for infections located in the genitourinary tract. It colonizes the genital mucosa, and then crosses the epithelium, subsequently invading the subepithelium, where it multiplies and is responsible for a severe inflammatory reaction. Disseminated gonococcal infections are possible, but remain rare and are the result of only some strains.

[0009] As regards Nl, it is considered that this is a non-pathogenic strain, since it is not responsible for a localized or general invasion.

[0010] A first consideration thus led to taking into account the fact that Nm and Ng, while being bacteria very close to one another, have different pathogenic potencies.

[0011] Since the genome of these bacteria has a high homology, only limited parts of the genome of Nm and Ng must code for specific virulence factors responsible for their pathogenesis.

[0012] It is clear that Nm has, compared with Ng, DNA sequences which are specific to it and which must be involved in the expression of its specific pathogenic potency.

[0013] The species Nm is subdivided into serogroups based on the nature of the capsular polysaccharides.

[0014] At least 13 serogroups have been defined, among which serogroups A, B and C are responsible for about 90% of meningitis cases. Groups A and C are found in epidemic forms of the disease. Group B is the serogroup generally isolated the most in Europe and the United States.

[0015] The capsule, which is present in Nm and absent from Ng, has served as the basis for formulating meningococcal antimeningitis vaccines.

[0016] The polysaccharides of the Nm capsule have been used to formulate a vaccine which has proved to be effective in preventing in adults the meningitis caused by meningococci of serogroups A, C, W135 and Y.

[0017] However, the polysaccharide of Nm group C has proved to be weakly immunogenic in children of less than two years, while the polysaccharide of Nm group B is non-immunogenic in man and shares epitopes with adhesion glycoproteins present in human neuronal cells.

[0018] There is therefore no universal vaccine capable of preventing infections caused by all the serogroups of the meningococci and capable of responding to the intrinsic antigenic variability of bacterial pathogens in general and Nm in particular.

[0019] Because of the cross-reactivity of the Nm group B polysaccharide with human antigens, the multiplicity of the serogroups and the antigenic variability of Nm, the strategies proposed to date cannot lead to a vaccine which is effective in all situations.

[0020] Research is therefore concentrated on study of the characteristic elements responsible for the specificity of the meningococcal pathogenesis.

[0021] The majority of genes which have been studied in either of the two bacteria Nm or Ng have their homologue in the second bacterium.

[0022] In the same way, the majority of virulence factors identified to date in Nm have a counterpart in Ng, that is to say pilin, the PilC proteins, the opacity proteins and the receptors of lactoferrin and transferrin.

[0023] The specific attributes of meningococci characterized in the prior art are the capsule, the Frp proteins analogous to RTX toxins, Opc proteins of the external member, glutathione peroxidase, the porin PorA and the rotamase gene.

[0024] Among these, only the capsule is invariably present in the virulent strains of Nm. However, several extracellular pathogens have a capsule without nevertheless crossing the haemato-encephalic barrier.

[0025] Attributes which have not yet been identified must therefore be responsible for the specificity of the meningococcal pathogenesis. These attributes are probably coded by DNA sequences present among the meningococci but absent from the gonococci.

[0026] The inventors have developed a new approach based on subtractive isolation of Nm-specific genes, which genes must be linked to the specific pathogenesis of Nm, and more particularly to crossing of the haemato-encephalic barrier.

[0027] The subtractive method developed in the prior art has resulted in the production of epidemological [sic] markers for some Nm isolates. These markers are of limited use: they do not cover all the serogroups of the Nm species.

[0028] In contrast to these studies, the work of the inventors has led, by confronting Nm with the entire Ng chromosome sheared in a random manner, to the development of a means for cloning all the DNAs present in Nm and absent from Ng, thus providing tools of high specificity with respect to Nm, and thus enabling the genetic variability of the species to be responded to for the first time.

[0029] The terms “present” and absent” used in the description and claims in relation to the DNAs of a strain or their expression products are interpreted on the basis of identical hybridization conditions (16 h at 65° C., with NaPO₄ 0.5 M, pH 7.2; EDTA-Na 0.001 M, 1%, 1% bovine serum albumin and 7% sodium dodecylsulphate) using the same probe and the same labelling intensity of the probe, the same amount of chromosomal DNA and the same comparison element (chromosomal DNA of the homologous strain).

[0030] It is therefore considered that the DNA is present if the signal obtained with the probe is practically the same as that obtained with the reference strain.

[0031] Conversely, it is considered that the DNA is absent if this signal appears very weak.

[0032] A second consideration of the pathogenicities of Nm and Ng leads to taking into account their common capacity for colonization and penetration of the mucosa, and then invasion of the subepithelial space of the latter. It is highly probable that this process involves virulence factors common to the two pathogens. In this respect, it is known that a certain number of virulence factors have already been identified in Nm and in Ng, such as the pili proteins, PilC, the opacity proteins, the IgA proteases, the proteins for binding to transferrin and to lactoferrin, and the lipooligosaccharides.

[0033] The approach of the inventors is thus extended to investigation of the Nm regions which are specific to Nm and Ng but absent from the non-pathogenic species Nl, and in a general manner to investigation of the chromosomal regions of the DNAs and their expression products specific to a given species by the means developed in accordance with the invention.

[0034] The object of the invention is thus to provide DNAs of Nm specific to its pathogenic potency and means for obtaining them, in particular by formulating banks formed exclusively from these Nm-specific DNAs.

[0035] It also provides the products derived from these DNA sequences.

[0036] The invention also relates to the utilization of specific and exhaustive characteristics of these banks to formulate tools which can be used, in particular, in diagnostics, treatment and prevention.

[0037] The DNAs of the invention are characterized in that they are in all or part genes, with their reading frame, present in Neisseria meningitidis, but absent both from Neisseria gonorrhoeae and from Neisseria lactamica, with the exception of genes involved in the biosynthesis of the polysaccharide capsule, frpA, frpc, opc, por A, rotamase, the sequence IS1106, IgA proteases, pilin, pilC, proteins which bind transferrin and opacity proteins.

[0038] As stated above, the terms “present” and “absent” are interpreted on the basis of the hybridization conditions used in the Southern blotting described in the examples and referred to above.

[0039] It can be seen that these DNAs include variants where these express a function intrinsic to the Nm species, more particularly a phenotype found solely in Nm or in common exclusively with Ng.

[0040] According to a main aspect, these DNAs are specific to the pathogenicity of Neisseria meningitidis, in spite of the genetic variability of this species.

[0041] According to an embodiment of the invention, the said DNAs are specific to Nm, in contrast to Ng.

[0042] More particularly, the Nm-specific DNAs are absent from Neisseria lactamica and from Neisseria cinerea.

[0043] Surprisingly, the majority of genetic differences between the strains of meningococci and those of gonococci appear grouped in distinct regions, which are said to correspond to the pathogenicity islets described previously for E. coli and Y. pestis.

[0044] In a preferred embodiment of the invention, these DNA are thus also characterized in that they comprise one or more sequence(s) present on the chromosome of Neisseria meningitidis Z2491 between tufA and pilT, or region 1 of the chromosome, and/or the sequence(s) capable of hybridizing with the above sequence(s), with the proviso of being specific to Neisseria meningitidis.

[0045] “Specific” in the description and the claims means the nucleotide sequences which hybridize only with those of Nm under the hybridization conditions given in the examples and referred to above.

[0046] In this respect, it can be seen that, in a general manner, when “all or part” of a sequence is referred to in the description and claims, this expression must be interpreted with respect to the specificity defined above.

[0047] Furthermore, all or part of a peptide or a fragment of a peptide or an antibody means a product having the biological properties respectively of the natural peptide or the antibody formed against the peptide.

[0048] Genes of the Neisseria meningitidis capsule are grouped in region 1.

[0049] DNAs of this type have a sequence corresponding in all or part to SEQ ID No. 9, 13, 22 or 30, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or have a sequence which is capable of hybridizing with at least a fragment of any one of these sequences.

[0050] In another preferred embodiment of the invention, these DNA are also characterized in that they are made up of one or more sequence(s) present on the chromosome of Neisseria meningitidis Z2491 between pilQ and λ740, or region 2 of the chromosome, and/or the sequences(s) capable of hybridizing with the above sequence(s), with the proviso of being specific to Neisseria meningitidis.

[0051] DNAs according to this embodiment have a sequence corresponding in all or part to SEQ ID No. 1, 2, 4, 6, 7, 10, 15, 31 or 34, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or have a sequence which is capable of hybridizing with at least a fragment of any one of these sequences.

[0052] The invention especially provides all or part of the DNA sequence SEQ ID No. 36 of 15,620 bp, and the sequences corresponding to the open reading frames SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44 and SEQ ID No. 45.

[0053] In yet another preferred embodiment of the invention, these DNAs are also characterized in that they are made up of one or more sequence(s) present on the chromosome of Neisseria meningitidis Z2491 between argF and opaB, or region 3 of the chromosome, and/or the sequence(s) capable of hybridizing with the above sequence(s), with the proviso of being specific to Neisseria meningitidis.

[0054] DNAs according to this embodiment are characterized in that they have a sequence corresponding in all or part to SEQ ID No. 8, 21, 23, 25, 26, 28, 29, 32 or 35, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or have a sequence which is capable of hybridizing with at least a fragment of any one of these sequences.

[0055] Regions 1, 2 and 3 identified above have a high proportion of sequences specific to Neisseria meningitidis and also fall within the context of the invention.

[0056] Other DNAs representative of the specificity with respect to Neisseria meningitidis have one or more sequences which is/are present on the chromosome of Neisseria meningitidis Z2491 but are not part of regions 1, 2 and 3 defined above.

[0057] Such DNAs comprise one or more sequence(s) corresponding in all or part to SEQ ID No. 3, 5, 11, 12, 14, 16, 18, 19, 20, 24, 27 or 33, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or have a sequence capable of hybridizing with such sequences.

[0058] Taking into account the uses envisaged in particular, the invention more specifically relates to the above DNAs involved in the pathogenesis of the bacterial organism.

[0059] In particular, it provides the DNAs corresponding to at least one of the characterizations given above and coding for a protein exported beyond the cytoplasmic membrane, and/or of which all or part of their sequence corresponds to the conserved region of the said DNAs.

[0060] According to another embodiment of the invention, the DNAs are thus common with those of Ng, but are absent from those of Nl.

[0061] These are more specifically the DNAs which are present on region 4 (arg J to reg F) or on region 5 (lambda 375 marker to pen A) on the chromosome of Nm Z2491 and/or are capable of hybridizing with the said DNAs present, with the proviso of being specific to Nm and Ng, in contrast to Nl.

[0062] “Specific to Nm and Ng in contrast to Nl” means the DNAs which hybridize with the DNAs of Nm and Ng under the hybridization conditions of the examples (see example 4 in particular).

[0063] The DNAs of regions 4 and 5 and those capable of hybridizing with these DNAs, with the proviso of expressing the intrinsic functions of Nm, have the advantage of intervening in a significant manner in the virulence of Nm, being involved in the stage of initial colonization and penetration and in the septicaemic dissemination.

[0064] According to other embodiments, the invention provides transfer and expression vectors, such as plasmids, cosmids or bacteriophages, comprising at least one DNA as defined above.

[0065] It also provides host cells transformed by at least one DNA as defined above.

[0066] Other host cells of the invention comprise genes or gene fragments specific to Nm, and are characterized in that their chromosome is deleted by at least one DNA according to the invention, in particular a DNA responsible for the pathogenicity. They are more specifically bacterial cells, in particular of Nm.

[0067] The invention also relates to the RNAs of which the sequence corresponds in all or part to the transcription of at least one DNA sequence or sequence fragment as defined above.

[0068] The invention also relates to the antisense nucleic acids of the DNAs as defined above, or of fragments of these DNAs.

[0069] These antisense nucleic acids carry, where appropriate, at least one substituent, such as a methyl group and/or a glycosyl group.

[0070] Other products which fall within the context of the invention include polypeptides.

[0071] These polypeptides are characterized in that they have an amino acid chain corresponding to all or part of a sequence coded by the nucleic acids defined above, or deduced from sequences of these nucleic acids.

[0072] They are advantageously polypeptides corresponding to all or part of the polypeptides exported beyond the cytoplasmic membrane, more specifically polypeptides corresponding to all or part of those coded by a conserved region.

[0073] As a variant, the polypeptides of the invention can be modified with respect to those corresponding to the nucleic acid sequences such that they are particularly suitable for a given use, in particular use as a vaccine.

[0074] Modification is understood as meaning any alteration, deletion or chemical substitution where this does not affect the biochemical properties of the corresponding natural polypeptides, more specifically of functional proteins exported at the periplasm and the external membrane.

[0075] Other products according to the invention include antibodies directed against the above polypeptides.

[0076] The invention thus provides polyclonal antibodies, and also monoclonal antibodies, characterized in that they recognize at least one epitope of a polypeptide as described above.

[0077] It also relates to fragments of these antibodies, more particularly the fragments Fv, Fab and Fab′2.

[0078] The invention also relates to the anti-antibodies which are capable of recognizing the antibodies defined above, or their fragments, by a reaction of the antigen-antibody type.

[0079] According to the invention, the various products considered above are obtained by a synthesis and/or biological route in accordance with conventional techniques.

[0080] The nucleic acids can also be obtained from banks made up of Nm-specific DNAs such as are formulated by a subtractive technique, this technique comprising:

[0081] mixing of two DNA populations,

[0082] realization of at least one subtractive hybridization-amplification iteration, and

[0083] collection of the desired DNA or DNAs, followed, where appropriate, by its/their purification with elimination of redundant sequences.

[0084] According to the invention, the two DNA populations originate respectively from a strain of Neisseria meningitidis, the so-called reference strain for which the specific bank must be constructed, and a strain of Neisseria, the so-called subtraction strain, having a homology in primary DNA sequences of greater than about 70% with the Neisseria meningitidis strain, the DNA sequences of the subtraction and reference strains being obtained respectively by random shearing, and by cleavage by a restriction endonuclease capable of producing fragments less than about 1 kb in size.

[0085] The invention provides in particular a process for obtaining Neisseria meningitidis-specific DNA banks, comprising the stages of

[0086] random shearing of the chromosomal DNA of a strain of Neisseria gonorrhoeae, the so-called subtraction strain, in particular by repeated passage through a syringe,

[0087] cleavage of the chromosomal DNA of a strain of Neisseria meningitidis, the so-called reference strain, preferably by a restriction enzyme producing fragments less than about 1 kb in size,

[0088] splicing of the DNA fragments of the reference strain, cleaved by the restriction enzyme, with suitable oligonucleotide primers,

[0089] realization of a subtractive hybridization-amplification iteration, by:

[0090] mixing of the two DNA populations under suitable conditions for hybridization of homologous sequences, and then

[0091] amplification of auto-reannealed fragments and collection of these fragments,

[0092] digestion of these fragments by a restriction enzyme and re-splicing with oligonucleotide primers, followed by a

[0093] purification of the spliced DNA and, where appropriate, a new iteration of the subtractive hybridization, comprising mixing of DNA fragments of Neisseria gonorrhoeae sheared as indicated above with DNA fragments of Neisseria meningitidis produced by the preceding iteration, followed, if desired, by cloning of the DNAs of the bank.

[0094] The primers used are oligodeoxynucleotide primers which are suitable for the restriction endonuclease used and allow insertion into a cloning site, such as the EcoRI site of the plasmid pBluescript. Such primers will advantageously be chosen among the oligodeoxynucleotides referred to in the sequence listing under SEQ ID no. 36 to 45.

[0095] The banks thus obtained are formed from DNAs which are specific to meningococci and absent from gonococci.

[0096] The specificity of the DNAs was verified, as described in the examples, at each iteration by Southern blots, with genes common to the subtraction strain and to the reference strain, or with the total DNA of each of the strains digested by a restriction endonuclease, such as ClaI.

[0097] At each iteration, the exhaustivity of the DNA bank was also verified by Southern blotting with probes known to be specific to the reference strain, that is to say for Neisseria meningitidis the frp, opc and rotamase genes in particular.

[0098] The experiments carried out showed that the banks obtained by the process of the invention are deficient in genes having a significant homology with species of Neisseria other than Neisseria meningitidis, for example the ppk or pilC1 genes, generally in only 2 or 3 iterations.

[0099] If necessary, two routes, which are not exclusive of each other, can be taken.

[0100] It is possible to proceed with an (n+1)^(th) iteration using the DNA of iteration n as the DNA population of the reference strain.

[0101] As a variant, a second bank independent of the first is constructed, with a restriction enzyme of different specificity to that used in the first bank, for example MboI.

[0102] In all cases, it is preferable to keep each of the products produced by each of the iterations performed.

[0103] The invention also provides the use of the subtractive technique described above to obtain banks of the DNAs common to Nm and Ng, but specific with respect to Nl.

[0104] Three different banks are advantageously constructed, two of them by digestion of the chromosomal DNA of Nm by MboI and Tsp5091, and the third by digestion of the chromosomal DNA of Nm with MspI. Two subtraction series allow the DNAs having the required specificity to be collected, as described in the examples.

[0105] The invention also relates to the process for obtaining these banks and the banks themselves.

[0106] It can be seen that, generally, the process of the invention can be used to obtain banks of DNAs specific to a given cell species, or to a given variant of the same species, where another species or another variant which is close genomically and expresses different pathogenic potencies exists.

[0107] Using the process of the invention, DNA banks specific to given species of cryptococci, Haemophilus, pneumococci or also Escherichia coli, or more generally any bacterial agent belonging to the same species and having different pathovars will advantageously be constructed.

[0108] Furthermore, from these banks the invention provides the means to have available virulence factors specific to a species or a given variant.

[0109] Such banks are therefore tools which are of great interest for having available attributes which are responsible for the specificity of a pathogen, this use being more specifically illustrated according to the invention by the obtaining of banks comprising the attributes responsible for the specificity of the meningococcal pathogenesis.

[0110] Study of the products of the invention, the nucleic acids, polypeptides and antibodies, has enabled an absolute specificity with respect ot Neisseria meningitidis, regardless of the strain and its variability, to be demonstrated.

[0111] These products are therefore particularly suitable for diagnosis or prevention of infections and meningitis caused by Neisseria meningitidis, whether in adults or children and regardless of the serogroups of the strain in question.

[0112] The method for diagnosis, according to the invention, of a meningococcal infection, and more particularly of meningococcal meningitis, by demonstration of the presence of Neisseria meningitis in an analytical sample is characterized by the stages of:

[0113] bringing into contact a sample to be analysed, that is to say a biological sample or a cell culture, and a reagent formulated from at least one nucleic acid as defined above, if appropriate in the form of a nucleotide probe or a primer, or, as a variant, from at least one antibody or a fragment of an antibody as defined above, under conditions which allow, respectively, hybridization or a reaction of the antigen-antibody type, and

[0114] detection of any reaction product formed.

[0115] If the reagent is formulated from a nucleic acid, this can be in the form of a nucleotide probe in which the nucleic acid or a fragment of the latter is labelled in order to enable it to be detected. Suitable markers include radioactive, fluorescent, enzymatic or luminescent markers.

[0116] As a variant, the nucleic acid is included in a host cell, which is used as the reagent.

[0117] In these various forms, the nucleic acid is used as such or in the form of a composition with inert vehicles.

[0118] If the reagent is compiled from an antibody, or a fragment of an antibody, this can be labelled for detection purposes. Most generally, a fluorescent, enzymatic, radioactive or luminescent marker is used.

[0119] The antibody or the antibody fragment used, which is labelled if appropriate, can be used as such or in the form of a composition with inert vehicles.

[0120] The sample used in the stage of bringing the components into contact is a biological sample produced by a mammal, such as cephalorachidian fluid, urine, blood or saliva.

[0121] The detection stage is carried out under conditions which allow the reaction product to be demonstrated when it is formed. Conventional means use fluorescence, luminescence, colour or radioactive reactions, or also autoriadography [sic] techniques. It is also possible to quantify the product.

[0122] The invention also relates to the labelled products, the nucleic acids and antibodies, as new products.

[0123] The method defined above can be used for diagnosis of an immune reaction specific to a meningococcal infection.

[0124] The reagent used is thus a polypeptide according to the invention, as coded by the said nucleic acid sequences, corresponding to the natural product or a polypeptide which is modified but has the biological and immunological activity of the corresponding natural polypeptide.

[0125] It is advantageously a polypeptide exported beyond the cytoplasmic membrane of Neisseria meningitidis, more particularly the part of such a polypeptide corresponding to the conserved region of the DNA.

[0126] The invention also relates to kits for carrying out the methods defined above. These kits are characterized in that they comprise:

[0127] at least one reagent as defined above, that is to say of the nucleic acid, antibody or polypeptide type,

[0128] products, in particular markers or buffers, which enable the intended nucleotide hybridization reaction or immunological reaction to be carried out, as well as use instructions.

[0129] The specificity of the products of the invention and their location on the chromosome of Neisseria meningitidis Z2491, either grouped in a region and able to be interpreted as pathogenicity islets, or isolated on the chromosome, impart to them a very particular interest for realization of vaccine compositions with a universal purpose, that is to say whatever the strain and the variability which it expresses. These compositions can include in their spectrum other prophylaxes, and can be, for example, combined with childhood vaccines.

[0130] The invention thus provides vaccine compositions which include in their spectrum antimeningococcal prophylaxis, intended for prevention of any infection which may be caused by Neisseria meningitidis, these compositions being characterized in that they comprise, in combination with (a) physiologically acceptable vehicle(s), an effective amount of polypeptides or anti-antibodies or their fragments as defined above, these products optionally being conjugated, in order to reinforce their immogenicity [sic].

[0131] Immunogenic molecules which can be used comprise the poliovirus protein, the tetanus toxin, or also the protein produced by the hypervariable region of a pilin.

[0132] As a variant, the vaccine compositions according to the invention are characterized in that they comprise, in combination with (a) physiologically acceptable vehicle(s), an effective amount:

[0133] of nucleic acids as defined above,

[0134] of transformed host cells as defined above, or

[0135] of Nm cells, the chromosome of which has been deleted

[0136] by at least one DNA sequence according to the invention involved in the pathogenicity of the bacterium. The nucleotide material used is advantageously placed under the control of a promoter of its expression in vivo and synthesis of the corresponding protein. To reinforce the immunogenicity, it is also possible to combine this nucleic material with a DNA or an RNA which codes for a carrier molecule, such as the poliovirus protein, tetanus toxin or a protein produced by the hypervariable region of a pilin.

[0137] The vaccine compositions of the inventions can be administered parenterally, subcutaneously, intramuscularly or also in the form of a spray.

[0138] Other characteristics and advantages of the invention are given in the examples which follow for illustration thereof, but without limiting its scope.

[0139] In these examples, reference will be made to FIGS. 1 to 11, which show, respectively,

[0140]FIGS. 1A, 1B, 1C, 1D, 1E, 1F and 1G: analysis of the subtractive bank Tsp5091,

[0141]FIG. 2: the distribution of the Nm-specific sequences, in contrast to Ng, on the chromosome of the strain Z2491 (left-hand part) and of Nm-specific sequences, in contrast to Nl (right-hand part),

[0142]FIGS. 3A to 3C: the reactivity of the clones of the 3 regions of the chromosome according to the invention towards a panel of strains of the genus Neisseria,

[0143]FIG. 4: the position in region 2 of the chromosome of Nm of oligonucleotides used as probes,

[0144]FIGS. 5, 6 and 7: the Southern blots of a panel of strains of the genus Neisseria, using parts of region 2 of Nm as probes,

[0145]FIGS. 8A to 8C: the Southern blots with 3 subtractive banks over a panel of 12 strains of Neisseria, and

[0146]FIGS. 9, 10 and 11: the reactivity of clones of the 3 subtractive banks with respect to Nm, Nl and Ng.

[0147] In the examples which follow, the following materials and methods were used:

[0148] Bacterial Strains

[0149] To obtain the subtractive banks, strain Z2491 of Nm (Achtman et al., 1991, J. Infect. Dis. 164, 375-382), the strains MS11 (Swanson et al., 1974, Infect. Immun. 10, 633-644) and the strains 8064 and 9764 of Nl were used, it being understood that any other strain of the species in question could be used.

[0150] In order to verify the specificity of these banks, 6 strains of Nm, 4 strains of Ng, one strain of Nl (Neisseria lactamica) and one strain of Nc (Neisseria cinerea) were used.

[0151] The six strains of Nm are: Nm Z2491 of serogroup A, Nm 8013 of serogroup C (XN collection), Nm 1121, no serogrouping possible (XN collection), Nm 1912 serogroup A (XN collection), Nm 7972 of serogroup A (XN collection) and Nm 8216 of serogroup B (XN collection).

[0152] The four strains of Ng are: Ng MS11 (Pasteur Institute, Paris), Ng 403 (Pasteur Institute, Paris), Ng 6934 (Pasteur Institute, Paris), Ng WI (isolated from a disseminated gonococcal infection), Ng 4Cl, Ng 6493 and Ng FA 1090.

[0153] The strains of Nl are Nl 8064 and Nl 9764 (XN collection), and that of Nc is Nc 32165 (XN collection).

[0154] Molecular Genetics Techniques

[0155] Unless indicated otherwise, the techniques and reagents used correspond to those recommended by Sambrook et al (Sambrook et al 1989, Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press). The oligodeoxynucleotides used in this study are: RBAm12, 3′ AGTGGCTCCTAG 54 (SEQ ID No.54) RBam24, 5′ AGCACTCTCCAGCCTCTCACCGAG 3′; (SEQ IN No.55) Jbam12, 3′ GATCCGTTCATG 5′; (SEQ ID No.60) JBAM24, 5′ ACCGACGTCGACTATCCATGAACG 3′; (SEQ ID No.61) REco12, AGTGGCTCTTAA; (SEQ ID No.56) REco24, 5′ AGCACTCTCCAGCCTCTCACCGAG 3′; (= RBam 24) JEco12, GTACTTGCTTAA; (SEQ ID No.62) JEco24, 5′ ACCGACGTCGACTATCCATGAACG 3′; (= JBam 24) NEco12, AATTCTCCCTCG; (SEQ ID No.64) NEco24, AGGCAACTGTGCTATCCGAGGGAG; (SEQ ID No.65).

[0156] Transfer to Membranes (Southern Blots)

[0157] The transfers to membranes were effected by capillary transfers to positively charged nylon membranes (Boehringer Mannheim). The hybridizations were carried out at 65° C. in a solution comprising NaPi [sic] 0.5 M pH 7.2/EDTA 1 mM/SDS 7%/BSA 1%. The membranes were washed in a solution comprising NaPi [sic] 40 mM pH 7.2/EDTA 1 mM/SDS 1%. The final washing was carried out at 65° C. for 5 min.

[0158] The probe frp obtained with oligonucleotides based on the frpA sequence corresponds to 2.4 kb of the 5′ end of the gene of the strain Z2491. The opc and rotamase probes corresponding to whole genes are produced from the strain Z2491 using oligonucleotides constructed on the basis of published sequences. The probes pilCl and ppk (polyphosphate kinase) correspond to inserts of the plasmids pJL1 and pBluePPK6001 respectively.

EXAMPLE 1 Construction of Banks of DNAs Present in Nm and Absent from Ng

[0159] a. “MboI” Bank

[0160] Construction

[0161] The DNA of Nm Z2491 was cleaved by the endonuclease MboI and subjected to two iterations of a method called CDA (comprehensive difference analysis) below. This method comprises subtractive hybridization in the presence of excess sheared DNA of Ng MS11 and amplification by PCR of those meningococcal sequences which, since they are absent from or do not have significant homology with the DNA of Ng MS11, could reanneal.

[0162] The chromosomal DNA of the strain Ng MS11 is sheared randomly by repeated passage through a hypodermic syringe until fragments of a size ranging from 3 to 10 kb are obtained. These DNA fragments are purified by extraction with phenol.

[0163] The chromosomal DNA of the strain Nm Z2491 is itself cleaved by the restriction endonuclease MboI. These DNA fragments (20 μg) are spliced with 10 nmol of annealed oligonucleotides RBam12 and RBam24. The excess primers are removed by electrophoresis over 2% agarose gel of low melting point. The part of the gel containing amplified fragments greater than 200 bp in size is excised and digested by β-agarase. These fragments are purified by extraction with phenol.

[0164] To carry out a subtractive hybridization (first iteration), 0.2 μg of the Nm DNA spliced with the RBam oligonucleotides is mixed with 40 μg Ng DNA in a total volume of 8 ml of a buffer EE 3× (a buffer EE 1× is composed of N-(2-hydroxyethyl)piperazine-N′-(3-propanesulphonic acid) 10 mM and EDTA 1 mM, and its pH is 8.0). This solution is covered with mineral oil and the DNA is denatured by heating at 100° C. for 2 min. 2 μl NaCl 5 M are added and the mixture is left to hybridize at 55° C. for 48 h. The reaction mixture is diluted to {fraction (1/10)} in a preheated solution composed of NaCl and buffer EE, and in then immediately placed on ice.

[0165] 10 μl of this dilution are added to 400 μl of PCR reaction mixture (Tris.HCl pH 9.0 10 mM; KCl 50 mM; MgCl₂ 1.5 mM; Triton X100 0.1%; 0.25 mM of each of the four triphosphate deoxynucleotides; Taq polymerase 50 units per ml). The mixture is incubated for 3 min at 70° C. to complete the ends of the reannealed meningococcal DNA fragments.

[0166] After denaturing at 94° C. for 5 min and addition of the oligonucleotide RBam24 in an amount of 0.1 nmol per 100 μl, the hybridizations are amplified by PCR (30 cycles of 1 min at 94° C., 1 min at 70° C. and 3 min at 72° C., followed by 1 min at 94° C. and 10 min at 72° C.; Perkin-Elmer GeneAmp 9600).

[0167] The amplified meningococcal fragments are separated from the primers and high molecular weight gonococcal DNAs on gel. They are digested by MboI and the oligonucleotides JBam12 and JBam24 are spliced to them again. These spliced DNAs are again purified over gel and extracted with phenol.

[0168] A second iteration of the subtractive hybridization is carried out on 40 μg of the randomly sheared Ng DNA and 25 ng of the DNA spliced with the JBam oligonucleotides obtained from the first iteration of the subtractive hybridization.

[0169] During this second iteration, amplification of the auto-annealed Nm DNA is effected with the aid of the oligonucleotide JBam24.

[0170] Specificity

[0171] In order to confirm their Nm specificity, the amplified sequences after the second iteration of the CDA method are labelled and used as a probe for the DNA digested by ClaI produced from a panel of six strains of Neisseria meningitidis, four of Neisseria gonorrhoeae, one of Neisseria lactamica and one of Neisseria cinerea.

[0172] The Southern blots obtained show that the amplified sequences resulting from the second iteration of the CDA method have a high reactivity with several bands corresponding to meningococci, and do not have a reactivity with the bands corresponding to the Ng, Nl and Nc strains.

[0173] The “MboI” bank thus appears to be Nm-specific.

[0174] Exhaustivity

[0175] In order to test the exhaustivity of the bank, all the products produced from the first and second iterations of the CDA method and also the initial chromosomal materials of Nm Z2481 [sic] and Ng MS11 are subjected to agarose gel electrophoresis, transferred to a membrane and brought into contact with probes comprising genes known to be meningococcus-specific, that is to say frp, opc and rotamase (Southern blotting).

[0176] As a result of these hybridizations, the Nm-specific gene frp is represented in the MboI bank by a fragment of 600 bp, but no activity is observed for the rotamase and opc genes. The MboI bank, although Nm-specific, therefore cannot be considered exhaustive.

[0177] Given their high specificity, the fragments produced by the second iteration of the CDA method for the MboI bank can nevertheless be cloned on the BamHI site of the plasmid pBluescript.

[0178] A sequence corresponding to any of the Nm-specific genes can be included in the subtractive bank only if it is carried by a restriction fragment of appropriate size. This condition is a function of two factors. Firstly, the probability that the largest fragments are entirely Nm-specific is low. Secondly, even if such fragments existed, they would be under-represented in the bank because of the limitations of the PCR technique, the amplification effectiveness of which decreases with increasing size of the fragments. Fragments greater that about 600 bp in size are not included in the bank. Because of the absence of Mbo fragments of suitable size from the chromosome of Nm Z2491, the rotamase and opc genes cannot be included in the bank. Any enzyme cannot by itself produce a small fragment corresponding to any Nm-specific gene. A second bank was therefore constructed using another restriction enzyme with a different specificity: Tsp509 [sic].

[0179] b. “Tsp5091” Bank

[0180] Construction

[0181] The enzyme Tsp5091 has the advantage of producing fragments of smaller size (less than about 1 kb) than the enzyme MboI.

[0182] Tsp509I recognizes the sequence AATT and leaves, projecting at 5′, a sequence of 4 bases compatible with EcoRI. The oligonucleotides used are Reco, Jeco and NEco.

[0183] The method followed conforms with that followed for construction of the “MboI” bank described above. However, higher quantities of meningococcal DNA were used for the first iteration of the subtractive hybridization in order to compensate for the higher number of fragments of low molecular weight produced by Tsp509I. For the first iteration, 400 ng Nm DNA fragments and, in the second, 25 ng Nm fragments are subjected to subtractive hybridization with 40 μg randomly sheared Ng DNA.

[0184] For the construction of this “Tsp509I” bank, as a control, a third iteration of the subtractive hybridization is carried out using 40 μg sheared Ng DNA and 0.2 ng Nm fragments resulting from a digestion by Tsp509I and a resplicing, with NEco adaptors, of the fragments obtained as a result of the second iteration.

[0185] Specificity

[0186] As described for the previous bank, the product resulting from the second iteration of the CDA method is labelled and used as the probe for a panel of strains of Neisseria.

[0187]FIG. 1A illustrates the Southern blot hybridization of products of the second iteration of the CDA method with the DNA digested by ClaI of: Nm in track a, Ng MS11 in track b, Nm 8013 in track c, Ng 403 in track d, Nm 1121 in track e, Ng 6934 in track f, Nm 1912 in track g, Ng WI (strain DGI) in track h, Nm 7972 in track i, Nl 8064 in track j, Nc 32165 in track k, Nm 8216 in track 1.

[0188] In contrast to the high reactivity observed with all the Nm strains, a low or no reactivity is observed with the Ng, Nl and Nc strains.

[0189] The specificity of the bank was studied earlier by reacting membrane transfers (Southern blots) of the products produced by each of the three iterations of the CDA method with probes corresponding to pilC1 and ppk. These two genes are common to Nm and Ng.

[0190]FIG. 1B shows an agarose gel after electrophoresis of the chromosomes of Nm Z2491 and Ng Ms11, digested by Tsp509 [sic], and products resulting from each of the iterations of the CDA method.

[0191] In track a 1 μg of the chromosome of Nm was deposited, in track b 1 μg of that of Ng, in track c 0.15 μg of the products resulting from the first CDA iteration, in track d 0.1 μg of those of the second iteration, in track e 0.05 μg of the third iteration, MW representing the molecular size markers.

[0192]FIGS. 1C and 1D show gels obtained as described in FIG. 1B after transfer to the membrane (Southern blots) and hybridization with pilC1 (FIG. 1C) and ppk (FIG. 1D).

[0193] At the end of the second iteration of the CDA method, the sequences corresponding to the pilC1 and ppk genes are completely excluded from the bank.

[0194] Exhaustivity

[0195] The exhaustivity of the bank was examined by reacting the products resulting from the subtractive hybridization with the probes corresponding to three Nm-specific genes (frp, rotamase and opc).

[0196] These Nm-specific probes react with the amplification products resulting from the first and second iteration of the subtractive hybridization.

[0197]FIGS. 1E, 1F and 1G show gels obtained as described in FIG. 1B after transfer to the membrane (Southern blots) and hybridization with frpA (FIG. 1E), rotamase (FIG. 1F) and opc (FIG. 1G).

[0198] However, a third iteration of the subtractive hybridization leads to the loss of Nm-specific sequences, since the fragments which react with the rotamase and opc genes are absent from this third iteration.

[0199] In consideration of all these data, it emerges that the products resulting from the second iteration of the CDA method are Nm-specific and also constitute an exhaustive bank of Nm-specific sequences.

[0200] The products resulting from this second iteration are cloned at the EcoRI site of the plasmid pBluescript.

[0201] The bank produced by Tsp509I is more exhautive [sic] than the bank produced by MboI, as the theory considerations based on the enzymatic production of smaller restriction fragments would suggest.

[0202] In accordance with this aspect, it should be noted that the Tsp509I bank is less redundant than the MboI bank, that is to say it comprises less duplication of clones. 86% of the clones of the Tsp509I bank correspond to distinct sequences, while only 43% of the clones correspond to distinct sequences in the MboI bank (data not shown).

[0203] The bank produced by Tsp509I thus constitutes a source of Nm-specific clones.

EXAMPLE 2 Analysis of the Clones of the Subtractive Bank

[0204] Cloning and Sequencing of the Nm-Specific DNAs

[0205] The DNAs of the subtractive banks are clones at the BamHI (MboI bank) or EcoRI (Tsp509I bank) site of the plasmid pBluescript, and then transformed in DH5α of E. coli. The inserts are amplified by PCR carried out on the transformed colonies using the primers M13-50 and M13-40, the latter primer being biotinylated on its 5′ end.

[0206] Sequencing was carried out on each PCR product after separation of the biotinylated and non-biotinylated strands using the system of Dynabeads M-280 with streptavidin (Dynal, Oslo). The sequences are screened according to their homologies with previously published sequences using the computer programs Blastn and Blastx (NCBI, USA and Fasta).

[0207] The PCR products resulting from the transformed bacteria colonies after using the primers M13-40 and M13-50 as described above were labelled by incorporation with random priming of α-³²P-dCTP and were used as a probe for the membrane transfers of the chromosomal DNA digested by ClaI of strains Nm Z2491 and Ng MS11, as described above, in order to verify their specificity.

[0208] Mapping of Clones on the Chromosome of the Strain Nm Z2491.

[0209] The results of studies carried out with 17 clones of the “MboI” bank (designated by the letter B) and 16 clones of the “Tsp5091” bank (designated by the letter E), each of these clones having a unique sequence and being without counterpart in Ng, are reported.

[0210] The positions of the DNA sequences corresponding to cloned Nm-specific products were determined with respect to the published map of the chromosome of Nm Z2491 (Dempsey et al. 1995, J. Bacteriol. 177, 6390-6400) and with the aid of transfers to membranes (Southern blots) of agarose gel subjected to pulsed field electrophoresis (PFGE).

[0211] The Nm-specific clones are used as probes for a hybridization on membranes (Southern blots) of the DNA of Nm Z2491 digested with enzymes of rare cutting sites, that is to say PacI, PmeI, SgfI, BglII, SpeI NheI and SgfI.

[0212] The gels (20×20 cm) were gels of 1% agarose in a buffer TBE 0.5× and were subjected to electrophoresis at 6 V/cm for 36 hours according to pulsation periods varying linearly between 5 and 35 seconds.

[0213] The hybridizations on the membrane (Southern blots) were carried out as described above.

[0214] The results obtained are shown on FIG. 2: the reactivity was located by comparison with the positions of the fragments of corresponding size on the published map. The positions of all the genetic markers mapped by Dempsey et al (mentioned above) are visualized with the aid of points on the to linear chromosomal map. The Nm-specific genes disclosed previously are labelled with an asterisk. The two loci called “frp” correspond to the frpA and frpc genes. The “pilC” loci correspond to the pilC1 and pilC2 genes, which are pairs of homologous genes and are not distinguished on the map. The accuracy of the positions of the Nm-specific clones of the invention depends on the overlapping of reactive restriction fragments. On average, the position is +/−20 kb.

[0215] This mapping reveals a non-random distribution of the Nm-specific sequences. The majority of the Nm-specific sequences belong to three distinct groups. One of these groups (region 1) corresponds to the position of genes relating to the capsule which have been described previously.

[0216] A distinction is made between:

[0217] E109, E138, B230 and B323 as being region 1,

[0218] B322, B220, B108, B132, B233, B328, E139, E145 as B101 as being region 2, and

[0219] B306, E114, E115, E124, E146, E120, E107, E137 and 142 as being region 3.

[0220] 63% of the sequences identified as specific to meningococci are located inside these three distinct regions.

[0221] This grouping contrasts with the distribution of previously disclosed Nm-specific genes (frpA, frpC, porA, opc and the region relating to the capsule).

[0222] This prior art would suggest in fact that the Nm-specific genes, with the exception of functional genes relating to the capsule, were dispersed along the chromosome.

[0223] Mapping of Nm-specific sequences on the chromosome leads to an unexpected result with regard to the prior art.

[0224] The majority of the genetic differences between the meningococcal and gonococcal strains tested are grouped in three distinct regions.

[0225] Meningococcal genes relating to the capsule are grouped in region 1.

[0226] The function of genes of the other regions is unknown, but homologies with published sequences (table 1) suggest similarities between certain genes of region 3 and bacteriophage transposase and regulatory proteins. No meningococcal virus has been characterized and it is tempting to think that these sequences are of phagic origin. Interestingly, the genome of H. influenzae also contains a sequence homologous to that of the Ner regulatory protein of phage Mu, but it is not known if it is a functional gene.

[0227] The clone B208 has a high homology (48% identical, 91% homology for 33 amino acids) with a clone of conserved regions field III) in the class of proteins which bind to TonB-dependent ferric siderophors.

[0228] The proximity of this clone with the Nm-specific porA genes and the frp genes regulated by iron, and in particular the possibility that it is an Nm-specific receptor protein exposed on the external membrane in itself is a good candidate for further research.

[0229] The clone B339 corresponds to the Nm-specific insertion sequence IS1106.

[0230] The low homology between the clone B134 and the Aeromonas insertion sequence and also the presence of multiple copies of the clone B134 among the various strains of Nm suggest that it could be a new type of Nm-specific insertion sequence.

[0231] The possibility that the regions containing the Nm-specific clones could correspond to pathogenicity islets as described previously for E. coli and Y. pestis is of particular interest.

[0232] The clones isolated in this invention will allow better understanding of the relevance of Nm-specific regions in allowing cloning and sequencing of larger chromosomal fragments, and directly by their use for loci mutations.

[0233] Finally, detection of meningococcus-specific genes possibly involved in the pathogenicity of the organism allows targeting of suitable antigens which can be used in an antimeningococcal vaccine.

[0234] The effectiveness and the speed of the method according to the inventions enables it to be used in a large number of situations for which the genetic differences responsible for a phenotype peculiar to one of 2 close pathogens are investigated.

[0235] Study of the Reactivity of the Clones of Regions 1, 2 and 3 Towards a Panel of Strains of Neisseria.

[0236] The PCR products corresponding to inserts of each of the clones were collected and used as probes for hybridization on membranes (Southern blots) for a panel of strains of Nm, Ng, Nl and Nc.

[0237] Regions 1 and 2 produce a limited number of bands for each of the meningococci. This suggests that these regions are both Nm-specific and common to all the meningococci.

[0238]FIG. 3 illustrates the reactivity of the clones of regions 1, 2 and 3 towards a panel of neisserial strains. The clones of regions 1 (FIG. 3A), 2 (FIG. 3B) and 3 (FIG. 3C) taken together were used as probes towards a panel of meningococci, gonococci and towards a strain of Nl and Nc.

[0239] The tracks are as follows: DNA of: Nm Z2491 in track a, of Ng MS11 in track b, of Nm 8013 in track c, of Ng 403 in track d, of Nm 1121 in track e, of Ng 6934 in track f, of Nm 1912 in track g, of Ng WI (strain DGI) in track h, of Nm 7972 in track i, of Nl 8064 in track j, of Nc 32165 in track k, and of Nm 8216 in track 1.

[0240] Remarkably, region 3 has reactivity only with the meningococci of serogroup A. This region 3 is therefore specific to a sub-group of Nm.

[0241] A comparison was made with the known sequences in the databanks in order to evaluate the possible functions of the cloned regions.

[0242] Table 1 which follows gives the positions of specific clones on the chromosomal map and the homologies with known sequences. TABLE 1 Position of specific clones on the chromosomal map and homologies with known sequences Size Reactive Position Name of of fragments on Homologies of protein clone* insert Pac Pmc Bg1 Spe Nhe Sgf Z2491 sequences B305 259 18-20 15-17 22-23 18  11- 2 λ736 13 B333 235 15-17 22-23 18  11- 2 λ736 13 E109¹⁺ 211 6-7 11-15 10  11- 2 tufA protein LipB 13 ctrA N. meningitidis (3 × 10⁻²⁶) E138¹⁺ 315  1 6-7 11-15 10  11- 2 tufA protein LipB 13 ctrA N. meningitidis (4 × 10⁻⁷⁵) B230¹ 356 1-3 6-7 1 10  11- 2 ctrA protein KpsC E. coli 13 (3 × 10⁻⁵³) B323¹ 363  1 6-7 1 10  11- 2 ctrA protein CtrB 13 N. meningitidis (2 × 10⁶⁴) B322² 210 2 16-18 6 1 5 pilQ/λ HlyB S. marcescens 740 (4 × 10⁻¹⁵) B220² 341 2 16-18 6 ≧18 5 pilQ/λ 740 B108² 275 2 19-21 6 ≧18 5 pilQ/λ 740 B132² 411  2 2 19-21 6 ≧18 5 pilQ/λ 740 B233² 164 1-3 2 19-21 6 ≧18 5 pilQ/λ 740 B328² 256 1-3 2 22-23 6 ≧18 5 pilQ/λ 740 E139² 324  2 2 19-21 6 ≧18 5 pilQ/λ 740 E145² 343  2 2 19-21 6 ≧18 5 pilQ/λ 740 B101² 254 ≧20   2 19-21 6 ≧18 5 pilQ/λ 740 E103q 334 2 11-15 3-5 10 3 λ644 B326^(§) 314 2 11-15 3-4 10 3 λ644 B326 (low 5 6 16  2 1 argF reactivity) B342 167 2 19  3-4 6-7 3 iga E136 249 2 7 1 3 3 lepA B208 177 1 2 3-4 2 1 porA FeIII pyochelin receptor P. aeruginosa (5.10⁻⁴) = B306^(3#) 219 11 5 11-12 5 2 4 parC E114³ 227 11 5 11-12 5 2 4 parC E115^(3#) 251 5 11-15 5 2 4 parC E124³ 208 5 11-12 5 2 4 parC E146³ 146 5 11-15 5 4 parC E120³ 263 5 3-4 5 16 4 opaB E107³ 248 11 14-17 3-4 5 16 4 opaB E137³ 274 14-17 3-4 5 16 4 opaB Transposase Bacteriophage D3112 (6 × 10⁻¹²) E142³ 230 14-17 3-4 5 16 4 opaB Protein Ner-Likc H. influenzae (6 × 10⁻²³) Protein binding to the DNA Ner, phage mu (3 × 10⁻¹⁸) E116 379 5-7 11-13 3-4 2 6-7 8 λ375 B313 436  9 9 3-4 13- 5 2 λ611 14 B341 201 8-10 9 3-4 13- 5 2 λ611 14 E102 238 11-13 3-4 19  5 2 λ601 Hypothetical protein H11730 H. influenzae (7 × 10⁻²⁴) B134 428 multiple transposase ISAS2 Aeromonas salmonicida (5 × 10⁻⁵) B339 259 multiple transposase IS 1106 N. meningitidis (6 × 10⁻⁴⁵)

[0243] Firstly, it can be seen that the clones of region 1 all correspond to genes involved in biosynthesis of the capsule. These genes have previously been studied among the Nm of serogroup B (Frosch et al. 1989, Proc. Natl. Acad. Sci. USA 86, 1669-1673 and Frosch and Muller 1993, Mol. Microbiol. 8 483-493).

[0244] With the exception of a low homology with the haemolysin activator of Serratia marcescens, the clones of region 2 have no significant homology with published sequences, either in the DNA or the proteins.

[0245] Two of the clones of region 3 have interesting homologies with proteins which bind to the DNA, in particular the bacteriophage regulatory proteins and transposase proteins.

[0246] Clone B208 has a high homology with one of the conserved regions in one class of receptors (TonB-dependent ferric siderophor).

[0247] Clones B134 and B339 hybridize with several regions of the chromosome (at least 5 and at least 8 respectively).

[0248] Data relating to the sequences show that clone B339 corresponds to the Nm-specific insertion sequence S1106.

[0249] The translation of the clone B143 has a limited homology with the transposase of an Aeromonas insertion sequence (SAS2) (Gustafson et al. 1994, J. Mol. Biol. 237, 452-463). We were able to demonstrate by transfer on a membrane (Southern blots) that this clone is an Nm-specific entity present in multiple copies in the chromosomes of every meningococcus of the panel tested.

[0250] The other clones have no significant homology with the published neisserial sequences, and furthermore nor with any published sequence. These clones therefore constitute, with the majority of the other clones isolated, a bank of totally new Nm-specific loci.

EXAMPLE 3 Study of Region 2 of the Nm Chromosome

[0251] Determination and characterization of the sequence of region 2

[0252] PCR amplification is carried out with the chromosomal DNA of strain Z2491 of serogroup A, sub-group IV-1 using oligonucleotide primers formulated from each of the sequences of clones of region 2 in several different combinations. The PCR products which overlap are sequenced from the 2 strands using the chain termination technique and automatic sequencing (ABI 373 or 377).

[0253] To prolong the sequence beyond the limits of the clones available, partial SauIIIA fragments of 15 kb of the strain Z2491 are cloned in Lambda DASH-II (Stratagene).

[0254] The phages containing the inserts overlapping region 2 are identified by hybridization with clones of this region as probes. The DNA inserted is sequenced from the ends of the inserts, and these sequences are used to formulate new primers which will serve to amplify the chromosomal DNA directly, and not the phagic DNA.

[0255] An amplification of the chromosomal DNA is obtained using these new primers and those of the sequence previously available.

[0256] These PCR products are also sequenced from the 2 strands, which leads to a complete sequence of 15,620 bp (SEQ ID No. 36). The reading frames of this sequence which start with ATG or GTG and are characterized by a high codon usage index are analysed.

[0257] This analysis reveals 7 ORFs of this type which fill the major part of the sequence of 15,620 bp. The positions of these ORFs are the following:

[0258] ORF-1: 1330 to 2970 (SEQ ID No. 37); ORF-2: 3083 to 9025 (SEQ ID No. 38); ORF-3: 9044 to 9472 (SEQ ID No. 39); ORF-4: 10127 to 12118 (SEQ ID No. 40); ORF-5: 12118 to 12603 (SEQ ID No. 41); ORF-6: 12794 to 13063 (SEQ ID No. 43); ORF-7: 13297 to 14235 (SEQ ID No. 44); and ORF-8: 14241 to 15173 (SEQ ID No. 45).

[0259] ORF-4 starts with the codon GTG and overlaps a slightly smaller ORF (SEQ ID No. 41) in the same reading frame (9620-12118, frame 2), which starts with the codon ATG.

[0260] ORF-4 codes for a protein which has structural homologies with a family of polypeptides comprising pyocins (Pseudomonas aeruginosa), collcins and intimins (Escherichia coli), which are bactericidal toxins (pyocins, collcins) or surface proteins involved in adhesion of bacteria to eukaryotic proteins. ORF-7 encodes a protein, the sequence of which contains a potentially transmembrane region and which has structural homologies with periplasmic proteins or proteins inserted in the external membrane of bacteria. The structural homologies of ORF-4 and ORF-7 have been identified with the aid of the PropSearch program.

[0261] Investigation of sequences homologous to other ORFs in GenBank with the aid of the BLAST program revealed a homology between the N-terminal regions of ORF-2 and filamentous haemagglutinin B of Bordetella pertussis (43% similarity, 36% identical over 352 amino acids) and between ORF-1 and the protein fhaC of Bordetella pertussis (35% similarity, 27% identical over 401 amino acids). ORF-1 and ORF-2 are neighbouring genes in the strain Z249I and filamentous haemagglutinin B of Bordetella pertussis and fhaC are neighbouring genes in Bordetella pertussis, which reinforces the probability that these homologies reflect functional homologies.

[0262] Confirmation of the specificity of region 2 with respect to Nm

[0263] Southern blots are carried out using the DNA probes obtained by PCR amplification of various parts of region 2 using oligonucleotide primers formulated from sequences of clones of region 2.

[0264] The approximate position of these oligonucleotides is shown on FIG. 4.

[0265] These are the oligonucleotides called R2001 (SEQ ID No. 46) and R2002 (SEQ ID No. 47) in one half of ORF-1, the oligonucleotides b332a (SEQ ID No. 48), e139a (SEQ ID No. 49), b132a (SEQ ID No. 50) and b233b (SEQ ID No. 51) in one half of ORF-1+the majority of ORF-2, and the oligonucleotides e145a (SEQ ID No. 52) and b101a (SEQ ID No. 53) in ⅓ of ORF-4+ORF-5 to 7.

[0266] The three Southerns are carried out under the following hybridization conditions:

[0267] 16 h at 65° C.,

[0268] NaPO₄ 0.5 M, pH 7.2

[0269] EDTA-Na 0.001 M

[0270] 1% sodium dodecylsulphate.

[0271] For the washing, heating is carried out for 10 min at 65° C., and NaPO₄ 0.5 M, pH 7.2; EDTA-Na 0.001 M, 1% sodium dodecylsulphate are used.

[0272]FIGS. 5, 6 and 7 respectively show the Southern blots obtained with each of the abovementioned ORF parts.

[0273] The 14 tracks correspond respectively, in each of the Southerns, to

[0274] 1: MS11 (Ng)

[0275] 2: 403 (Ng)

[0276] 3: FA1090 (Ng)

[0277] 4: W1 (Ng)

[0278] 5: 6493 (Ng)

[0279] 6: marker (lambda hindIII)

[0280] 7: Z2491 (Nm, gpA)

[0281] 8: 7972 (Nm gpA)

[0282] 9: 8013 (Nm, gpC)

[0283] 10: 1121 (Nm, grouping not possible)

[0284] 11: 1912 (Nm, gpB)

[0285] 13: 32165 (Nc)

[0286] 14: 8064 (Nl).

[0287] Given that a panel of strains of Neisseria is used in these experiments and that each well is charged with a similar amount of digested DNA, these 3 Southern blots clearly show that the sequences corresponding to region 2 are found in all the meningococci tested and that significant homologous sequences do not exist in the genome of the Ng of the strains tested.

EXAMPLE 4 Identification of Regions of the Nm Genome Absent from Nl and Common with Ng

[0288] The technique described in example 1 is followed, but the chromosomal DNA of one strain of Nm (Z2491) and 2 strains of Nl (XN collections), equal parts of the DNAs of which are mixed, is used.

[0289] 2 subtractions are performed using the R and J series of primers. Three different banks are thus obtained.

[0290] Two banks, called Bam and Eco, are obtained respectively by digestion of the chromosomal DNA of Nm Z2491 by MboI and Tsp5091; a third bank, called Cla, which results from digestion of the chromosomal DNA of Nm by MspI, is obtained using the primer set RMsp10, RMsp24, JMsp10 and JMsp24. All the primers used are shown in the following table 2. TABLE 2 Adapters for differential banks Chromosomal DNA Cloning in digested by pBluescript by MboI → BamHI Tsp509I → EcoRI MspI → ClaI

[0291] First subtraction cycle RBam12: 3′ AGTGGCTCCTAG 5′ (SEQ ID No.54) RBam24: 5′ AGCACTCTCCAGCCTCTCACCGAG 3′ (SEQ ID No. 55) REco12: AGTGGCTCTTAA (SEQ ID No.56) RBam24: 5′ AGCACTCTCCAGCCTCTCACCGAG 3′ (SEQ ID No. 55) (REco 24 = RBam 24) RMsp10: AGTGGCTGGC (SEQ ID No.57) RMsp24: 5′ AGCACTCTCCAGCCTCTCACCGAC 3′ (SEQ ID No. 58) Second subtraction cycle Jbam12: 3′ GTACTTGCCTAG 5′ (SEQ ID No.59) JBam24: 5′ ACCGACGTCGACTATCCATGAACG 3′ (SEQ ID No. 60) JEco12: GTACTTGCTTAA. (SEQ ID No. 61) JBam24: 5′ ACCGACGTCGACTATCCATGAACG 3′ (SEQ ID No 60) (JEco 24 = TBam 24) JMsp10: GTACTTGGGC (SEQ ID No. 62) JMsp24: 5′ ACCGACGTCGACTATCCATGAACC 3′ (SEQ ID No. 63)

[0292] After 2 subtractions, the entire product of each amplification is labelled and used as a probe.

[0293] The subtractive banks are checked by Southern blotting over a panel of 12 strains of Neisseria (chromosomal DNA cut by ClaI). The hybridization conditions are identical to those given in example 1.

[0294] These Southern blots are shown on FIGS. 8A to 8C, which relate respectively to the MboI/BamHI bank, to the MspI/ClaI bank and to the Tsp5091/EcoRI bank. The 12 tracks correspond respectively, to

[0295] 1: Nm Z2491 (group A)

[0296] 2: Nl 8064

[0297] 3: Nm 8216 (group B)

[0298] 4: Nl 9764

[0299] 5: Nm 8013 (group C)

[0300] 6: Ng MS11

[0301] 7: Nm 1912 (group A)

[0302] 8: Ng 4C1

[0303] 9: Nm 1121 (grouping not possible)

[0304] 10: Ng FAlO9O

[0305] 11: Nc 32165

[0306] 12: Nm 7972 (group A)

[0307] Examination of the Southern blots shows that the sequences contained in each bank are specific to Nm and are not found in Nl. Furthermore, the reactivity found with the strains of Ng suggests that some of these sequences are present in Ng.

[0308] Each of these banks was then cloned in pBluescript at the BamHI site for Bam, or the EcoRI sit for Eco, or the ClaI site for Cla. In order to confirm the specificity of the clones with respect to the Nm genome, restriction of the individual clones and radiolabelling thereof were carried out. The clones showing reactivity for both Nm and Ng were kept for subsequent studies. These clones are shown on FIGS. 9, 10 and 11, which give the profiles with respect ot Nm, Nl and Ng of 5 clones of the Bam bank (FIG. 9), 16 clones of the Eco bank (FIG. 10) and 13 clones of the Cla bank (FIG. 11).

[0309] These clones were sequenced using universal and reverse primers. They are

[0310] Bam clones

[0311] partial B11 of 140 bp (SEQ ID No. 66), partial B13 estimated at 425 bp (SEQ ID No. 67), B26 of 181 bp (SEQ ID No. 68), B33 of 307 bp (SEQ ID No. 69), B40 of 243 bp (SEQ ID No. 70),

[0312] Cla clones

[0313] C16 of 280 bp (SEQ ID No. 72), partial C20 estimated at 365 bp (SEQ ID No. 73), partial C24 estimated at 645 bp (SEQ ID No. 74), partial C29 estimated at 245 bp (SEQ ID No. 75), C34 of 381 bp (SEQ ID No. 76), C40 of 269 bp (SEQ ID No. 77), C42 of 203 bp (SEQ ID No. 78), p C43 of 229 bp (SEQ ID No. 79), C45 of 206 bp (SEQ ID No. 80), C47 of 224 bp (SEQ ID No. 81), C62 of 212 bp (SEQ ID No. 82), and C130 (5′ . . . ) estimated at 900 bp (SEQ ID No. 83), and

[0314] Eco clones

[0315] E2 of 308 bp (SEQ ID No. 84), partial E5 estimated at 170 bp (SEQ ID No. 85), partial E22 estimated at 300 bp (SEQ ID No. 86), E23 of 273 bp (SEQ ID No. 87), E24 of 271 bp (SEQ ID No. 88), E29 of 268 bp (SEQ ID No. 89), partial E33 estimated at 275 bp (SEQ ID No. 90), partial E34 estimated at 365 bp (SEQ ID No. 91), E45 of 260 bp (SEQ ID No. 92), E59 estimated at greater than 380 bp (SEQ ID No. 93), E78 of 308 bp (SEQ ID No. 94), E85 of 286 bp (SEQ ID No. 95), E87 of 238 bp (SEQ ID No. 96), partial E94 greater than 320 bp (SEQ ID No. 97), partial E103 greater than 320 bp (SEQ ID No. 98) and E110 of 217 bp (SEQ ID No. 99).

[0316] Mapping of each clone was carried out on the chromosome of Nm Z2491 as described in example 1. The results obtained are given on the right-hand part of FIG. 2. It is found that these clones correspond to regions called 4 and 5. These regions are therefore made up of sequences present both in Nm and in Ng, but not found in Nl. It is therefore regarded that these are sequences which code for virulence factors responsible for the initial colonization and penetration of the mucosa. Region 4 is located between argF and regF on the chromosome of Nm 2491 [sic], and region 5 is located between the lambda 375 marker and penA. This region probably contains sequences which code for an Opa variant and a protein which binds transferrin.

[0317] A comparison with the known sequences in the databanks has half [sic] that in region 4 only the clone C130 has a homology, that is to say with MspI methylase. In region 5, no homology with known sequences was found with the clones C8, E2, B40, C45, E23 and E103. For the other clones, the homologies are the following:

[0318] B11 arginine decarboxylase SpeA; C29 arginine decarboxylase SpeA; C62 oxoglutarate/malate transporter; repetitive DNA element; E34 repetitive DNA element; E94 murine endopeptidase MepA; C47 citrate synthase PrpC; E78 citrate synthase PrpC

EXAMPLE 5 Demonstration of the Presence of One or More Strains of Neisseria meningitidis in a Biological Sample

[0319] A biological sample of the cephalorachidian fluid, urine, blood or saliva type is taken.

[0320] After filtration and extraction, the DNAs present in this sample are subjected to gel electrophoresis and transferred to a membrane by Southern blotting.

[0321] A nucleotide probe constructed by labelling SEQ ID No. 5 with ³²P is incubated with this transfer membrane.

[0322] After autoradiography, the presence of reactive band(s) allows diagnosis of the presence of Neisseria meningitidis in the sample.

EXAMPLE 6 Vaccine Composition Including in its Spectrum Antimeningocococcal Prophylaxis and Intended for Prevention of any form of Infection by Neisseria meningitidis

[0323] The peptide coded by a sequence including SEQ ID No. 10 is conjugated with a toxin.

[0324] This conjugated peptide is then added to a composition comprising the anti-Haemophilus and antipneumococcal vaccine, or any other childhood vaccine.

[0325] After having been sterilized, the resulting composition can be injected parenterally, subcutaneously or intramuscularly.

[0326] This same composition can also be sprayed on to mucosa with the aid of a spray.

1 99 257 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 1 GATCCGCTGC CGGCAGACGA ATATCAAGAC ATCTTCGATT TTATGAAACA GTATGACTTG 60 TCTTACCCGT ATGAATATCT GCAGGATTGG ATAGATTACT ATACGTTCAA AACCGATAAG 120 CTGGTATTTG GTAACGCGAA GCGAGAGTGA GCCGTAAAAC TCTGAGCTCC TGTTTTATAG 180 ATTACAACTT TAGGCCGTCT TAAAGCTGAA AGATTTTCGA AAGCTATAAA TTGAAGCCCT 240 TCCACAGTAC ATAGATC 257 276 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 2 GATCATGTTC AAATAGATAG GCATGGGAAG CTGCAGCTCT AACGTCCATG AAAATATGTT 60 GCATAGCTGC AAGCGGAACG CCTTTTCTTT CATCTACATA ATCTATAGAG TCAAGGCAAC 120 CGCTATTGAA ATTAGCAGTA TTGCCTATGA TTACATTAGT AATATGCTCA TACCATTTTT 180 GGGTGGTCAT CATATTGTGC CCCATTGTTA TCTCCTTATA TTGGTTTTAG AAGGAACTTT 240 GACAGGAAGA ATAACGGCCT TACCTGTTTG ACGATC 276 428 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 3 GATCTGGTGG TGTTTGCACA GGTAGGCGCA TACTTGTTCG GGACTGAGTT TGCGGCGGAT 60 AAGGGTGTCG ATGTGCTGAA TCAGCTGCGA ATCGAGCTTA TAGGGTTGTC GCTTACGCTG 120 TTTGATAGTC CGGCTTTGCC GCTGGGCTTT TTCGGCGCTG TATTGCTGCC CTTGGGTGCG 180 GTGCCGTCTG ATTTCGCGGC TGATGGTGCT TTTGTGGCGG TTAAGCTGTT TGGCGATTTC 240 GGTGACGGTG CAGTGGCGGG ACAGGTATTG GATGTGGTAT CGTTCGCCTT GGGTCAGTTG 300 CGTGTAGCTC ATGGCAATCT TTCTTGCAGG AAAGGCCGTA TGCTACCGCA TACTGGCCTT 360 TTTCTGTTAG GGAAAGTTGC ACTTCAAATG CGAATCCGCC GACCTCTTTC AGTTACAGCA 420 GCTTGATC 428 390 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 4 GATCCTGCAT TGACATCGGC CTTGGCTGTC AGGGTATTGT GACCGGTAAA GTCGGCATTA 60 CCGTTGGCCA ATAAGGATAC ATGACCGTCT GCAGAAACAG CATGAAGGCC GTCTGAAACG 120 ATATTGCCCT GCAATGCGGT GGTTTCGAGA GCCTTGGCTG CGTTCAGCTT GGTATTGCGA 180 AGCTGAATAT TGCCTTTGGC TGCCTGAATG TGCAGATTAC CCGAGTTGGT ACGCAGATTG 240 GTATTGGTAA CATTCAGCAA GCCTGCCTCC ACACCCATGT CTTTTGAGGC AGTGAGGGTT 300 TTACTGGTGC CGGTAATATG GGCAGCGTTA TCCGATTTCA AATGGATGCT GGCCGGCAGA 360 CAAATCTTTA TCAACATTCA AATTCAGATC 390 177 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 5 GATCAGATTG GTGAAGACGG TATTACCGTC AATGTTGCAG GCCGTTCGGG ATATACGGCG 60 AAAATCGACG TGTCTCCGAG TACCGATTTG GCGGTTTATG GCCATATTGA AGTTGTACGG 120 GGTGCAACGG GGTTGACCCA ATCCAATTCA GAGCCGGGTG GAACCGTCAA TTTGATC 177 341 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 6 GATCAATGAT GCTACTATTC AAGCGGGCAG TTCCGTGTAC AGCTCCACCA AAGGCGATAC 60 TGAATTGGGT GAAAATACCC GTATTATTGC TGAAAACGTA ACCGTATTAT CTAACGGTAG 120 TATTGGCAGT GCTGCTGTAA TTGAGGCTAA AGACACTGCA CACATTGAAT CGGGCAAACC 180 GCTTTCTTTA GAAACCTCGA CCGTTGCCTC CAACATCCGT TTGAACAACG GTAACATTAA 240 AGGCGGAAAG CAGCTTGCTT TACTGGCAGA CGATAACATT ACTGCCAAAA CTACCAATCT 300 ACTCCC GGCAATCTGT ATGTTCATAC AGGTAAAGAT C 341 164 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 7 GATCCAACTG TTTGATTTTA CTGGCTGCTT CTCCATGCGC GGTATTGACC AAAGCCGCAA 60 GGATATTCGC TTCCAGATTG TCTTTCAGGC TGCCGCCGTT GACAGCGGTA TTAATCAGTG 120 CGGCACTGCC CGCATTGGCT AGGTTGACGG TCAGGTTGTT GATC 164 219 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 8 GATCAATCAC ACATCTTGTC ATTTTTTCGA TTCCTTCATT TCGGTTTCTA ATGTTTCAAT 60 TCTTGCGGCC ATTTCCTGAA TGGCTTTAGT CAAAACGGGG ATGAACGCTT CGTATTCGAC 120 GGTGTAGGTA TCGTTTGTTT TATTTACCAT CGGCAATCGA CCATATTCAT CTTCCAGCGC 180 AGCAATGTCC TGGGCAATAA ACCAATGCCG CAACCGATC 219 356 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 9 GATCTTGGGT AAGCCCCCAA CCTGCATAGA AAGGCAGGCC GTAGCAGCTG ACTTTTTTGC 60 CGCGCAACAA GGCTTCAAAA CCGGTCAGCG AAGTCATGGT ATGTATTTCG TCTGCGTATT 120 GGAGACAGGT CAGGATGTCG GCTTGTTCGG CGGTTTGGTC GGCATATCGT GCAGCATCAT 180 CAGGGGAAAT ATGGCCGATG CGGTTACCGC TGACTACATC GGGATGCGGT TTGTAGATGA 240 TATAGGCATT GGGGTTTCGT TCGCGTACGG TACGGAGCAA ATCCAGATTG CGGTAGATTT 300 GGGGCGAACC GTAGCGGATA GACGCATCAT CTTCAACCTG GCCGGGAACG AGGATC 356 210 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 10 GATCCGCTTT CAGTTTCCGT ACCGGTGGCA TCAGTCAAGT CCGTTTTGTG CACCAAACCG 60 CGTCCATATG AAACATAAAA CAAATCGCTT AAGCCCAAAG GGTTATCGAA CGATAAAGCG 120 ACATTTCCTT GATATTTGCC GGTCGTTTTG CCGCCCGCAT CATCTATACC GATACTGAAC 180 CGTATGGGTT TATTCTGCTG CCATTTGATC 210 259 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 11 GATCCCGAAA CGCAATTGGT CGAAAGCTAT ATGCTGAACG ATGTGTTGCG GTTTTGGGAC 60 AGCGCAGGTT TGGGCGATGG GAAAGAAGCC GACCGCGCCC ATCGGCAAAA ACTGATTGAT 120 GTCCTGTCTA AAACCTATAC TCATTCGGAT GGGCAGTGGG GCTGGATAGA TTTGGTGTTC 180 GTTATCCTTG ACGGCAGCTC CCGCGATTTG GGTACGGCCT ATGATTTGTT GAGGGATGTT 240 ATCCTTAAAA TGATTGATC 259 436 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 12 GATCAAATGG ATGATTTATA TAGAATTTTC TTTTACGACT GCGTGCCGTT TGAAAAGAAA 60 ATGCACAATC CCGTATCTCA TCGTGCCATA GATTTTTCAA AGACTCCGGA AGCCATATTT 120 CGTTGCAATC TGCATACCGA ATTGAAGAAG AAGCGTAAAT TAGCGTTACG TTTAGGCAAG 180 CTGTCGGACA ATACAGCATG GATATTAAAA CCCCAAGTCA TGAAAAATCT TCTGAAAAAC 240 CCGTCAACTC AAATTACGGA AAACGATGTC GTGCTCGATG TTAAACAAAA AGGTGTAGAT 300 ATGCGTATAG GCTTGGATAT TTCATCTATT ACCTTAAAAA AACAAGCCGA TAAAATCATC 360 TTGTTTTCTG GTGATTCCGA TTTTGTCCCA GCAGCCAAAT TAGCCAGACG GGAAGGTATC 420 GATTTTATTC TTGATC 436 363 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 13 GATCGTTTTA CGTCGCAATC GAGCTTTGTG GTGCGCTCGC CTAAAAGCCA ATCTTCTCTC 60 AATGGCCTGG GTGCCATTTT GCAGGGCACA GGTTTTGCCC GTGCGCAAGA CGATATTTAT 120 ACCGTGCAGG AATATATGCA GTCGCGTTCG GCTTTGGATG CGTTGCGTAA GAAAATGCCC 180 ATTCGCGATT TTTATGAAAA AGAAGGCGAT ATTTTCAGCC GTTTTAATGG TTTTGGCCTG 240 CGTGGCGAGG ATGAGGCGTT TTATCAATAC TACCGTGATA AGGTATCCAT CCATTTTGAC 300 TCTGTCTCAG GCATTTCCAA TTTGAGCGTT ACATCGTTTA ATGCCGGTGA ATCTCAAAAG 360 ATC 363 314 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 14 GATCTTGCGT CATTTATATC TTCACCGATA TTGCAATTAC CGCCGTTCCA GTTGAAATAA 60 CAACGACTAA AATTGTAGTT CCTAAAAGAA TCATTCCTAT TCTTGCGTAC CATTTCCCAA 120 TAATTGCGCC CGACAATTTC CATTTAATGC TCCATCAGTT CTTTTACTTC CGGAAATCTG 180 CTGTAATCTG ACATAAGACG CATAATTGAA CTATCAACGC CGTAACAGCC ATAGGTTTTA 240 ATACCGTTTT CGGCGTGTTC CCAAATGCAA TTACTGTATT CGTAGCCTTT TACAAATTTA 300 TCGGTTTCGG GATC 314 256 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 15 GATCATACGA ATCTACCCTA AAATACCCCG TCGCCGATTT AGGATTGGCT ACATAAAGCT 60 CATTATAAGG GTATTTTGAT GACATGATAC GGTTAAATTC ATTGCCGTTG TTTATCCTGA 120 TTCTATAAAT TGGTTCAACA GCAAAGCCTC TGGATTCCCT TAATTGATTA TAATATTGCC 180 TGTATGTTTG TACATCATGT CTTGTCCACG GCTCTCCAGG AGTCCTCAGA ATAGCAATCC 240 CGTTAAATTT CGGATC 256 235 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 16 GATCCACGCC TGTGCCTACC TTGGCTTTTT GTTCGCCAAA CAAGGCATTT AAGGTTGAGG 60 ACTTGCCGAC ACCTGTCGCA CCGACAAGCA AGACATCCAA ATGACGGAAA CCGGCTGCTG 120 TGACTTTTTG CCCGATTTCA GAAATACGGT AACGATGCAT ATGCGCTCCT ACCAGCCAAA 180 AAAAGAAGCA ACCGTGCTAA TCGCCCCTCC AATCGCTTTT GCAGCACCGC CGATC 235 259 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 17 GATCCAACGG GCATCGCTGT CCTTACTCGG TGTGGTTTGA CCGCTGATTT GTCCTTCTTC 60 GTCAACTTCT ATGGCCTGAC GCTGTTTGCT GCCGGCGGTC TGGATAATGG TGGCATCAAC 120 GACGGCGGCG GATGCTTTCT CTATTTTTAG GCCTTTTTCG GTCAGTTGGC AGTTAATCAG 180 TTTGAGTAAT TCGGACAGGG TGTCGTCTTG CGCCAGCCAG TTGCGGTAGC GGCATAAGGT 240 ACTGTAATCG GGGATGATC 259 201 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 18 GATCTGTGCC GTTGATTTTA TCTTTCAGAT GCAGCATCGA ATATCGGAAA GCCAAATCAG 60 CAATTCTTTT TGCATCGTGT GGATTTTGAG ACGGGCCTAA TGACCGTACC CGCTTAATAA 120 AAAATGCACC GTCAATCAAA ATGGCGGTTT TCATATTGCT TCCCCTATAT TTGTCAAAGA 180 TATAAAAAAG CCCTTGGGAT C 201 334 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 19 AATTCAAAGG AGGCATTTGT TGCAAGAAAA GTACAAAGTG ATTTGCAAAA AGCATTGAAT 60 GCTAGCAACT ATAACAAGCA GCAATATGCA AGACGTGCGG CAACAGCGTT AGAGAATGCT 120 TCAAAATCAA AAGTTATGGC AGCGAATTCT TTTTGATCTA TCTTGTGCGA ACGGGTCAAA 180 TATTCTTCGT ACATTGAGTT AATCGTACCA ATCGCCCTAA CCACATTTTC ATCAGAAAAT 240 ATGGAAATAA TAGCATCCCT ATACGCACCT AGTGTAATAT TGTTTCTATT ATTAGTTATA 300 GCATTATTCG AATACATAAT AGCACCTCCA AATT 334 238 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 20 AATTCCTGCG CACCTTTGCC GATGGGGAGA TAATCGCCTT TTTGCAGCAT TCTGCCCTGA 60 TGGCCGCCGA AACCGGCTTT CAGGTCGGTA CTTCTCGAAC CCATCACTTC CGGCACATCA 120 AATCCGCCCG CCACGCACAC ATAGCCGTAC ATGCCCTGCA CGGCACGCAC CAGTTTCAAG 180 GTCTGCCCTT TGCGGGCGGT ATAACGCCAA TACGAATAGA CCGGTTCGCC GTCCAATT 238 249 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 21 AATTGGGCGA GATGCTGCCG GAAACGGATT TAAAACAGAT TGCGGCGGCA GTGTTGAAGA 60 CGAACGATGA GGCGGCATTG CAGAAGGTGG TGAAAACGGC CAAAGGCAAT GCGCGGAAAC 120 TGTCGAAGCT GCTGCTGATT GTGGACTATT TGTTGCAGGT TAACCCTGAT GTTGATTTGG 180 ATGATGATGT AATCGAACAC GCGGAAACCT ATTTAATCCA CTAAACCTTT GACAGATAAG 240 GCAATAATT 249 212 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 22 AATTTATGTA CGGTTTTGCC GTTTGCAGTC AGCCAGTCGG CAAGGCGCAG AAAAAAATCG 60 CCGACAGGGC CTTGAAGCAG CAGGATATTT TCTGCGCTTT CAAGCAGGTT TTGCAGGTTA 120 TTTTTGAGGA CGGTCTGTTT CATGTTGCAA TGTGGTTTTG TTTTTTATGT AATAGTTTTA 180 GGTTGAACTT TCAAGCATAC GCCAAGAGAA TT 212 227 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 23 AATTCAGTGC CTGCGTCATA TCACGGCTAC CTTGTGGTTC AGGGTTACTG TATCGCCCGC 60 GGCATCGACG GCTTCAATAT GCAGCTTCAG CCAGCCGTGC TGCGGGGCGG ATGCGGTTAC 120 TTGGATGGAT TGGGCGCGTT TGGACTGAAT CACGGGCTGC AAGGCTTGCT CGGCGTACTG 180 TTTGGCCAGT ACTTCGATGC GCTTTAAATG CTTTTGGCGG CGCAATT 227 167 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 24 GATCCAGGAC TCAAAAACCG ATTTCCTAAT AGAGTGTCTA ATATCCCAAT CTTTTTTACC 60 CCCTCTGCTG TAGAATTGAT AGAGAAAGTT TGTCTATCTT TTTCATATAC CCATGCCTTC 120 TTTTTATCAT TGTAGCTAAC ATAACCGCCA AACAATGCTT CTAGATC 167 251 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 25 AATTCTTGCG GCCATTTCCT GAATGGCTTT AGTCAAAACG GGGATGAACG TTTCGTATTC 60 GACGGTGTAG GTATCGTTTG TTTTATTTAC CATCGGCAAT CGACCATATT CATCTTCCAG 120 CGCAGCAATG TCCTGGGCAA TAAACCAATG CCGCAACCGA TCTTCTTTAT GACTGCCGTC 180 CTTGATTGGA TTCGCCCACC ATTCGCGGAC TTTGTCCGCT CGTTCATCTG CCGGCAAGTC 240 TTTGAATAAT T 251 207 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 26 AATTCCCGAC TATCGCGGAT GCGTAGTTTT TGCCGGTGGG CAAGAGCAGG TGTGGGATAA 60 GTTAGGTGAT TTGCCCGATG GCGTCAGCCT GACCCCGCCT GAATCGGTAA ATATTGACGG 120 CTTAAAATCC GTAAAACTCG TCGCATTAAA TGCTGCCGCT CAGGCTTTTA TTAACAAGCA 180 CGCCGGTATC GACAGCGTAC CTGAATT 207 379 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 27 AATTGTTTGG GAATAATCCA AACAAACAGC ATCAGGATAG CGGCGGCGGT CAGGCTGCCT 60 GAAAGGATTT TGCCGGGGTT TTTTGTAGGC AAAGCGGACG AGAAACCAAA GCAACAGCAG 120 CATGGTGTCC CAATAGCCGA TTGAGAATAG GATGGCCAAA CCTTCTAGGA AATGGCGTAA 180 ATCGTTTGTG GTAACCATGG GTAGTTCCTG TGGTTAAATG TGCAGGCTGC TTTTTGCCGA 240 ACCTTGCCGC ATCTCAAAAG CAGCCTGCGC TTCAGCGTTG CGTTACGCAG TAAAATAATG 300 AATATTTGTA ACGGCTTGGG TATTTTTTGT CAATATTCCC GCCCTTCCCT TAACAGCTGC 360 CGCGCTTTCC GTTAAAATT 379 274 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 28 AATTCGCCGA AATCAGGCTG CTGCTCGATA ATCGGCGCGG CCGATTGGCG TTGTGCCTCG 60 ATTAAATCCA TCTTGTCTTG CAGACGTTTG GCCTGGCCTT TGCGGCGGCG TTCGGCCAGT 120 TGTTCCATCC GCGTTTCCGC AAATGCCGCC CGTTTGTTGC CGTTGAATAC CGCTTTGCAA 180 ATCACCTTGC CCTGCATATC CTTCACAATC ACATGGTCGG CATCGTGGAT GTCGTAAGCC 240 ACCCGTACCT TCTGACCGCT GTAATCCAGC AATT 274 263 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 29 AATTCCGTTC TTATTGGGCT TTTTCCATCC ATCGGGTATG CCTGAAGGGA ACGCAAACCC 60 TGCCACTTGC CCATCGCTCC ATTCCCGCAT TAGCGCGTCT GACGGCAAGT GTTCTCGCGC 120 CCAATCAAGC CACGCCTGCC GCATTGCGGC CTTGTCCTGC TGAAAACTTC GCAGTGCTTT 180 TGCAACCGGC CCATCATTAA CTTCAATCAA ATAAATCATT ATATTTGCGT TCATTTTTCC 240 TACACCTTCG CCACATCCAA ATT 263 316 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 30 AATTGTTCAA GAAAAAAGTC GGCACGGCGC GGCAACGGGG AAAATGCGTT GACGCCGTCT 60 TTTTCTAAGG TGATGTAGTA GGGGCGGAAA TAGCCTTCTT CAAACGCCCA GAAACTGGCT 120 TGGTTTTCGT TTGCAATGCG TTTTGCAATG ACGTGATAAG GGCGTGTGTC GCCAAAGCAG 180 ACAACGGCCT GGATGTGATG TTGAGTGATG TATTCTTGCA AAAACTCAGG AAAGGCGTCG 240 TAGTTGTCGT TAAAAACAAC GGTATGCGCT TGAGTGGGCG GATAAAAATA GTCGTCGCCT 300 GCATTAAAGT TGAATT 316 324 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 31 AATTCAATCA ACGGAAAACA CATCAGCATC AAAAACAACG GTGGTAATGC CGACTTAAAA 60 AACCTTAACG TCCATGCCAA AAGCGGGGCA TTGAACATTC ATTCCGACCG GGCATTGAGC 120 ATAGAAAATA CCAAGCTGGA GTCTACCCAT AATACGCATC TTAATGCACA ACACGAGCGG 180 GTAACGCTCA ACCAAGTAGA TGCCTACGCA CACCGTCATC TAAGCATTAC CGGCAGCCAG 240 ATTTGGCAAA ACGACAAACT GCCTTCTGCC AACAAGCTGG TGGCTAACGG TGTATTGGCA 300 CTCAATGCGC GCTATTCCCA AATT 324 230 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 32 AATTATGCAA AAAAACGCAA CGCCGAAAAA CTGGCACCGC GCGGATATTG TTGCTGCTTT 60 GAAAAAGAAA GGCTGGTCAC TTCGAGCACT TTCAATAGAA GCGGGGTTGT CGCCGAATAC 120 GCTTAGAAGC GCACTGGCCG CCCCTTATCT TAAGGGAGAA AGGATTATTG CCGCTGCAAT 180 CGGAGTGGAA CCGGAAGAGA TTTGGTCCGA ACGGTATGCA GATCGGAATT 230 249 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 33 AATTTAATCG GTGGAATGCC TGTTCAACCG CACCAATCCC GCTGAATACG GTTGCTAATC 60 TAATATGTGA ATCAGGTTTA AGAAAAGTTT TAGATTTCCA ACCTTGTTGA CTGGGAAAGA 120 GCAAAGTTTT TTGTAATCGA GTATCGTGTG TCTGTGCCAT TGTCGAAATA GTCATACTTA 180 TATCGTTCTG TTTATCTTAT CAATATGAAA ACTACATCGT TGATTGCCCT GACAATGCCT 240 TGGTCAATT 249 343 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 34 AATTCTTGTC CCGGAGTCCA ACGTATATTT ACCCTCCTGC GAGCTAAAAG ACTATTATTC 60 TCCACTGCCA CAGTAGCCGC ATTCACCGCC GTATTCACAT CCCCTTTAAC CAATGCCACT 120 GCGCTGCCTG CGATAATCTG CGAGTAGGCT ATGACTTTTT GGCGTTCTTG GGGTGACAGT 180 TTGCCTACAT CGCGTCCGTC CAACAGGGTT TCTCCCACCA TCTCGCCGAC TGCCGCGCCG 240 ATTGCGCCGT CCCGACATTT GCCTTTATTT GCTACCGCCG ATGCACAGCC TGCTACGGCA 300 TGGGCTATCT TGTGGGCAAT GTAGTCTTCG CTGAGATTAA ATT 343 184 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 35 AATTCTTCAA ACATCGTTTC GATAATCGGG TCGGTGTACA CACTGATGCG GTCGCCCGCA 60 CGGCTTTGAC CGGCTCGGAA AATATAGGCG GTGGCTTTGC CGTCGGCGAT GTCGACGCAC 120 CAACGCCAGA TGGCGTCTTC GGTATTCAAA CAATCACCCG CACAGCTTTC ACCTGCGCGG 180 AATT 184 15620 base pairs nucleotide single linear DNA (genomic) Neisseria meningitidis Z2491 36 TATGCTCAAT CTCATTTTCA AAATGCAAAA CTTTTCTGAT TTTTCCTACT TTTTGCTCAA 60 TATTAGGAAG GTTTTAGGCA ATTGAAAATT TTTTGGCGCA TTTTTATGCG TCAAATTTCG 120 TTAACAGACT ATTTTTGCAA AGGTCTCCGT CTGTAAAAGC AAGGATAGGG CATCTGCCCT 180 TTTGATTGTT TGATTAACGA TACAAGGAGT TTCAAAATGA GAGTTTTATA GTGGATTAAC 240 AAAAACCAGT ACAGCGTTGC CTCGCCTTGC CGTACTATTT GTACTGTCTG CGGCTTCGTC 300 GCCTTGTCCT GATTTAAATT TAATCCACTA TATGTGTTCA TGAAATGACT TGGGTCGGAG 360 GCTCAGGTAA TGCGCAACAA AGTTCATATT ATTGCGAAAT TTGCGAATCT GCAGGGCTTA 420 ACGATACGGG AAATCCTGAT AAATCTTTAG GATTGCCAAA CAATACGTTC AGTAATCCGC 480 CTGGTTGGGG AGCTACAATC GGAGCTTTAG CAGGTAGCCG CATAGGTATG CCTGAATTTG 540 GTACGTTTGC GAGCCATGCC ATTGAAAATT TCGACTGGTC ATGGTATCGA CGTTATAGGG 600 AAATTGCCGA AACGATTGAA CGAGAATATT CAGGCGGTTT GCCTTAATAG TTGAGGAGGT 660 CATGATGTTT GCCAAACATT ATCAATTCAT CGCACTCGGC ATCATGCTGC TTCTTTATAT 720 GTTGATTCTC TATACGACCG ATTTTTCCAA TCTGACGTAT TGGATGCTGT TTTTTATCTG 780 TTTTATTACA GGAAAAATAT TAGCTCGTTT GTTAGAGAAA AGCTTTAAAT AAAATAGCAG 840 CTAGTCGCAA AAGGTCGTCT GAAACCTTTT CAGGCGGCCT TTCTAAAATA CATCCAACTT 900 CCTAATCCCT ATTTTTCAAA AAGGAAATCT ATGCCCCATC TGCAAAACCT GTCTTTGGGC 960 TTAAAGAAAA AGCTGCCTGT TATCCTGCAA ACAGAAATAT CAGAATGCGG CTTGGCATGT 1020 CTGGCGGCTG TGGCGGGATT TCATGGTTTC CATACGAATT TACGCGCACT GCGTTCAAAA 1080 TACTGTCCGA GACCTTTGCA AAATTCCCCA AAATCCCCTA AATGTCTTGG TGGGAATTTT 1140 GGGGAATTTT GCAAAGGTCT CATTCTATAA CTGTAAATAC TTTTAAATTT ATGACAAAAT 1200 AGTAAATATT GCTAAAATAA TATTGATGTC ATGAAATTTT TTCCTGCTCC ATGTCTGTTG 1260 GTTATCCTGG CTGTCATACC CCTTAAAACC TTAGCTGCCG ATGAAAACGA TGCAGAACTT 1320 ATCCGTTCCA TGCAGCGTCA GCAGCACATA GATGCTGAAT TGTTAACTGA TGCAAATGTC 1380 CGTTTCGAGC AACCATTGGA GAAGAACAAT TATGTCCTGA GTGAAGATGA AACACCGTGT 1440 ACTCGGGTAA ATTACATTAG TTTAGATGAT AAGACGGCGC GCAAATTTTC TTTTCTTCCT 1500 TCTGTGCTCA TGAAAGAAAC AGCTTTTAAA ACTGGGATGT GTTTAGGTTC CAATAATTTG 1560 AGCAGGCTAC AAAAAGCCGC GCAACAGATA CTGATTGTGC GTGGCTACCT CACTTCCCAA 1620 GCTATTATCC AACCACAGAA TATGGATTCG GGAATTCTGA AATTACGGGT ATCAGCAGGC 1680 GAAATAGGGG ATATCCGCTA TGAAGAAAAA CGGGATGGGA AGTCTGCCGA GGGCAGTATT 1740 AGTGCATTCA ATAACAAATT TCCCTTATAT AGGAACAAAA TTCTCAATCT TCGCGATGTA 1800 GAGCAGGGCT TGGAAAACCT GCGTCGTTTG CCGAGTGTTA AAACAGATAT TCAGATTATA 1860 CCGTCCGAAG AAGAAGGCAA AAGCGATTTA CAGATCAAAT GGCAGCAGAA TAAACCCATA 1920 CGGTTCAGTA TCGGTATAGA TGATGCGGGC GGCAAAACGA CCGGCAAATA TCAAGGAAAT 1980 GTCGCTTTAT CGTTCGATAA CCCTTTGGGC TTAAGCGATT TGTTTTATGT TTCATATGGA 2040 CGCGGTTTGG TGCACAAAAC GGACTTGACT GATGCCACCG GTACGGAAAC TGAAAGCGGA 2100 TCCAGAAGTT ACAGCGTGCA TTATTCGGTG CCCGTAAAAA AATGGCTGTT TTCTTTTAAT 2160 CACAATGGAC ATCGTTACCA CGAAGCAACC GAAGGCTATT CCGTCAATTA CGATTACAAC 2220 GGCAAACAAT ATCAGAGCAG CCTGGCCGCC GAGCGCATGC TTTGGCGTAA CAGGTTTCAT 2280 AAAACTTCAG TCGGAATGAA ATTATGGACA CGCCAAACCT ATAAATACAT CGACGATGCC 2340 GAAATCGAAG TGCAACGCCG CCGCTCTGCA GGCTGGGAAG CCGAATTGCG CCACCGTGCT 2400 TACCTCAACC GTTGGCAGCT TGACGGCAAG TTGTCTTACA AACGCGGGAC CGGCATGCGC 2460 CAAAGTATGC CCGCACCTGA AGAAAACGGC GGCGGTACTA TTCCAGGCAC ATCCCGTATG 2520 AAAATCATAA CCGCCGGATT GGATGCAGCG GCCCCGTTTA TGTTGGGCAA ACAGCAGTTT 2580 TTCTACGCAA CCGCCATTCA AGCTCAATGG AACAAAACGC CTTTGGTTGC CCAAGACAAG 2640 TTGTCTATCG GCAGCCGCTA CACCGTTCGC GGATTTGATG GGGAGCAGAG TCTTTTCGGA 2700 GAGCGAGGTT TCTACTGGCA GAATACTTTA ACTTGGTATT TTCATCCGAA CCATCAGTTC 2760 TATCTCGGTG CGGACTATGG CCGCGTATCT GGCGAAAGTG CACAATATGT ATCGGGCAAG 2820 CAGCTGATGG GTGCAGTGGT CGGCTTCAGA GGAGGGCATA AAGTAGGCGG TATGTTTGCT 2880 TATGATCTGT TTGCCGGCAA GCCGCTTCAT AAACCCAAAG GCTTTCAGAC GACCAACACC 2940 GTTTACGGCT TCAACTTGAA TTACAGTTTC TAACCTCTGA ATTTTTTTAC TGATATTTAG 3000 ACGGTCTTTC CTTATCCTCA GACTGTCAAA CTTTACCTAC GTACTTGGCG CGCAGTACGT 3060 TCATCTTCAA AATGGAATAG ACATGAATAA AGGTTTACAT CGCATTATCT TTAGTAAAAA 3120 GCACAGCACC ATGGTTGCAG TAGCCGAAAC TGCCAACAGC CAGGGCAAAG GTAAACAGGC 3180 AGGCAGTTCG GTTTCTGTTT CACTGAAAAC TTCAGGCGAC CTTTGCGGCA AACTCAAAAC 3240 CACCCTTAAA ACCTTGGTCT GCTCTTTGGT TTCCCTGAGT ATGGTATTGC CTGCCCATGC 3300 CCAAATTACC ACCGACAAAT CAGCACCTAA AAACCAGCAG GTCGTTATCC TTAAAACCAA 3360 CACTGGTGCC CCCTTGGTGA ATATCCAAAC TCCGAATGGA CGCGGATTGA GCCACAACCG 3420 CTATACGCAG TTTGATGTTG ACAACAAAGG GGCAGTGTTA AACAACGACC GTAACAATAA 3480 TCCGTTTCTG GTCAAAGGCA GTGCGCAATT GATTTTGAAC GAGGTACGCG GTACGGCTAG 3540 CAAACTCAAC GGCATCGTTA CCGTAGGCGG TCAAAAGGCC GACGTGATTA TTGCCAACCC 3600 CAACGGCATT ACCGTTAATG GCGGCGGCTT TAAAAATGTC GGTCGGGGCA TCTTAACTAT 3660 CGGTGCGCCC CAAATCGGCA AAGACGGTGC ACTGACAGGA TTTGATGTGC GTCAAGGCAC 3720 ATTGACCGTA GGAGCAGCAG GTTGGAATGA TAAAGGCGGA GCCGACTACA CCGGGGTACT 3780 TGCTCGTGCA GTTGCTTTGC AGGGGAAATT ACAGGGTAAA AACCTGGCGG TTTCTACCGG 3840 TCCTCAGAAA GTAGATTACG CCAGCGGCGA AATCAGTGCA GGTACGGCAG CGGGTACGAA 3900 ACCGACTATT GCCCTTGATA CTGCCGCACT GGGCGGTATG TACGCCGACA GCATCACACT 3960 GATTGCCAAT GAAAAAGGCG TAGGCGTCAA AAATGCCGGC ACACTCGAAG CGGCCAAGCA 4020 ATTGATTGTG ACTTCGTCAG GCCGCATTGA AAACAGCGGC CGCATCGCCA CCACTGCCGA 4080 CGGCACCGAA GCTTCACCGA CTTATCTCTC CATCGAAACC ACCGAAAAAG GAGCGGCAGG 4140 CACATTTATC TCCAATGGTG GTCGGATCGA GAGCAAAGGC TTATTGGTTA TTGAGACGGG 4200 AGAAGATATC AGCTTGCGTA ACGGAGCCGT GGTGCAGAAT AACGGCAGTC GCCCAGCTAC 4260 CACGGTATTA AATGCTGGTC ATAATTTGGT GATTGAGAGT AAAACTAATG TGAACAATGC 4320 CAAAGGCTCG GCTAATCTGT CGGCCGGCGG TCGTACTACG ATCAATGATG CTACTATTCA 4380 AGCGGGCAGT TCCGTGTACA GCTCCACCAA AGGCGATACT GAATTGGGTG AAAATACCCG 4440 TATTATTGCT GAAAACGTAA CCGTATTATC TAACGGTAGT ATTGGCAGTG CTGCTGTAAT 4500 TGAGGCTAAA GACACTGCAC ACATTGAATC GGGCAAACCG CTTTCTTTAG AAACCTCGAC 4560 CGTTGCCTCC AACATCCGTT TGAACAACGG TAACATTAAA GGCGGAAAGC AGCTTGCTTT 4620 ACTGGCAGAC GATAACATTA CTGCCAAAAC TACCAATCTG AATACTCCCG GCAATCTGTA 4680 TGTTCATACA GGTAAAGATC TGAATTTGAA TGTTGATAAA GATTTGTCTG CCGCCAGCAT 4740 CCATTTGAAA TCGGATAACG CTGCCCATAT TACCGGCACC AGTAAAACCC TCACTGCCTC 4800 AAAAGACATG GGTGTGGAGG CAGGCTTGCT GAATGTTACC AATACCAATC TGCGTACCAA 4860 CTCGGGTAAT CTGCACATTC AGGCAGCCAA AGGCAATATT CAGCTTCGCA ATACCAAGCT 4920 GAACGCAGCC AAGGCTCTCG AAACCACCGC ATTGCAGGGC AATATCGTTT CAGACGGCCT 4980 TCATGCTGTT TCTGCAGACG GTCATGTATC CTTATTGGCC AACGGTAATG CCGACTTTAC 5040 CGGTCACAAT ACCCTGACAG CCAAGGCCGA TGTCAATGCA GGATCGGTTG GTAAAGGCCG 5100 TCTGAAAGCA GACAATACCA ATATCACTTC ATCTTCAGGA GATATTACGT TGGTTGCCGG 5160 CAACGGTATT CAGCTTGGTG ACGGAAAACA ACGCAATTCA ATCAACGGAA AACACATCAG 5220 CATCAAAAAC AACGGTGGTA ATGCCGACTT AAAAAACCTT AACGTCCATG CCAAAAGCGG 5280 GGCATTGAAC ATTCATTCCG ACCGGGCATT GAGCATAGAA AATACCAAGC TGGAGTCTAC 5340 CCATAATACG CATCTTAATG CACAACACGA GCGGGTAACG CTCAACCAAG TAGATGCCTA 5400 CGCACACCGT CATCTAAGCA TTACCGGCAG CCAGATTTGG CAAAACGACA AACTGCCTTC 5460 TGCCAACAAG CTGGTGGCTA ACGGTGTATT GGCACTCAAT GCGCGCTATT CCCAAATTGC 5520 CGACAACACC ACGCTGAGAG CGGGTGCAAT CAACCTTACT GCCGGTACCG CCCTAGTCAA 5580 GCGCGGCAAC ATCAATTGGA GTACCGTTTC GACCAAGACT TTGGAAGATA ATGCCGAATT 5640 AAAACCATTG GCCGGACGGC TGAATATTGA AGCAGGTAGC GGCACATTAA CCATCGAACC 5700 TGCCAACCGC ATCAGTGCGC ATACCGACCT GAGCATCAAA ACAGGCGGAA AATTGCTGTT 5760 GTCTGCAAAA GGAGGAAATG CAGGTGCGCC TAGTGCTCAA GTTTCCTCAT TGGAAGCAAA 5820 AGGCAATATC CGTCTGGTTA CAGGAGAAAC AGATTTAAGA GGTTCTAAAA TTACAGCCGG 5880 TAAAAACTTG GTTGTCGCCA CCACCAAAGG CAAGTTGAAT ATCGAAGCCG TAAACAACTC 5940 ATTCAGCAAT TATTTTCCTA CACAAAAAGC GGCTGAACTC AACCAAAAAT CCAAAGAATT 6000 GGAACAGCAG ATTGCGCAGT TGAAAAAAAG CTCGCCTAAA AGCAAGCTGA TTCCAACCCT 6060 GCAAGAAGAA CGCGACCGTC TCGCTTTCTA TATTCAAGCC ATCAACAAGG AAGTTAAAGG 6120 TAAAAAACCC AAAGGCAAAG AATACCTGCA AGCCAAGCTT TCTGCACAAA ATATTGACTT 6180 GATTTCCGCA CAAGGCATCG AAATCAGCGG TTCCGATATT ACCGCTTCCA AAAAACTGAA 6240 CCTTCACGCC GCAGGCGTAT TGCCAAAGGC AGCAGATTCA GAGGCGGCTG CTATTCTGAT 6300 TGACGGCATA ACCGACCAAT ATGAAATTGG CAAGCCCACC TACAAGAGTC ACTACGACAA 6360 AGCTGCTCTG AACAAGCCTT CACGTTTGAC CGGACGTACG GGGGTAAGTA TTCATGCAGC 6420 TGCGGCACTC GATGATGCAC GTATTATTAT CGGTGCATCC GAAATCAAAG CTCCCTCAGG 6480 CAGCATAGAC ATCAAAGCCC ATAGTGATAT TGTACTGGAG GCTGGACAAA ACGATGCCTA 6540 TACCTTCTTA AAAACCAAAG GTAAAAGCGG CAAAATCATC AGAAAAACCA AGTTTACCAG 6600 CACCCGCGAC CACCTGATTA TGCCAGCCCC CGTCGAGCTG ACCGCCAACG GTATCACGCT 6660 TCAGGCAGGC GGCAACATCG AAGCTAATAC CACCCGCTTC AATGCCCCTG CAGGTAAAGT 6720 TACCCTGGTT GCGGGTGAAG AGCTGCAACT GCTGGCAGAA GAAGGCATCC ACAAGCACGA 6780 GTTGGATGTC CAAAAAAGCC GCCGCTTTAT CGGCATCAAG GTAGGTAAGA GCAATTACAG 6840 TAAAAACGAA CTGAACGAAA CCAAATTGCC TGTCCGCGTC GTCGCCCAAA CTGCAGCCAC 6900 CCGTTCAGGC TGGGATACCG TGCTCGAAGG TACCGAATTC AAAACCACGC TGGCCGGTGC 6960 CGACATTCAG GCAGGTGTAG GCGAAAAAGC CCGTGTCGAT GCGAAAATTA TCCTCAAAGG 7020 CATTGTGAAC CGTATCCAGT CGGAAGAAAA ATTAGAAACC AACTCAACCG TATGGCAGAA 7080 ACAGGCCGGA CGCGGCAGCA CTATCGAAAC GCTAAAACTG CCCAGCTTCG AAAGCCCTAC 7140 TCCGCCCAAA TTGTCCGCAC CCGGCGGCTA TATCGTCGAC ATTCCGAAAG GCAATCTGAA 7200 AACCGAAATC GAAAAGCTGT CCAAACAGCC CGAGTATGCC TATCTGAAAC AGCTCCAAGT 7260 AGCGAAAAAC ATCAACTGGA ATCAGGTGCA GCTTGCTTAC GACAGATGGG ACTACAAACA 7320 GGAGGGCTTA ACCGAAGCAG GTGCGGCGAT TATCGCACTG GCCGTTACCG TGGTCACCTC 7380 AGGCGCAGGA ACCGGAGCCG TATTGGGATT AAACGGTGCG GCCGCCGCCG CAACCGATGC 7440 AGCATTCGCC TCTTTGGCCA GCCAGGCTTC CGTATCGTTC ATCAACAACA AAGGCGATGT 7500 CGGCAAAACC CTGAAAGAGC TGGGCAGAAG CAGCACGGTG AAAAATCTGG TGGTTGCCGC 7560 CGCTACCGCA GGCGTAGCCG ACAAAATCGG CGCTTCGGCA CTGAACAATG TCAGCGATAA 7620 GCAGTGGATC AACAACCTGA CCGTCAACCT AGCCAATGCG GGCAGTGCCG CACTGATTAA 7680 TACCGCTGTC AACGGCGGCA GCCTGAAAGA CAATCTGGAA GCGAATATCC TTGCGGCTTT 7740 GGTCAATACC GCGCATGGAG AAGCAGCCAG TAAAATCAAA CAGTTGGATC AGCACTACAT 7800 AGTCCACAAG ATTGCCCATG CCATAGCGGG CTGTGCGGCA GCGGCGGCGA ATAAGGGCAA 7860 GTGTCAGGAT GGTGCGATAG GTGCGGCTGT GGGCGAGATA GTCGGGGAGG CTTTGACAAA 7920 CGGCAAAAAT CCTGACACTT TGACAGCTAA AGAACGCGAA CAGATTTTGG CATACAGCAA 7980 ACTGGTTGCC GGTACGGTAA GCGGTGTGGT CGGCGGCGAT GTAAATGCGG CGGCGAATGC 8040 GGCTGAGGTA GCGGTGAAAA ATAATCAGCT TAGCGACAAA GAGGGTAGAG AATTTGATAA 8100 CGAAATGACT GCATGCGCCA AACAGAATAA TCCTCAACTG TGCAGAAAAA ATACTGTAAA 8160 AAAGTATCAA AATGTTGCTG ATAAAAGACT TGCTGCTTCG ATTGCAATAT GTACGGATAT 8220 ATCCCGTAGT ACTGAATGTA GAACAATCAG AAAACAACAT TTGATCGATA GTAGAAGCCT 8280 TCATTCATCT TGGGAAGCAG GTCTAATTGG TAAAGATGAT GAATGGTATA AATTATTCAG 8340 CAAATCTTAC ACCCAAGCAG ATTTGGCTTT ACAGTCTTAT CATTTGAATA CTGCTGCTAA 8400 ATCTTGGCTT CAATCGGGCA ATACAAAGCC TTTATCCGAA TGGATGTCCG ACCAAGGTTA 8460 TACACTTATT TCAGGAGTTA ATCCTAGATT CATTCCAATA CCAAGAGGGT TTGTAAAACA 8520 AAATACACCT ATTACTAATG TCAAATACCC GGAAGGCATC AGTTTCGATA CAAACCTAAA 8580 AAGACATCTG GCAAATGCTG ATGGTTTTAG TCAAGAACAG GGCATTAAAG GAGCCCATAA 8640 CCGCACCAAT TTTATGGCAG AACTAAATTC ACGAGGAGGA CGCGTAAAAT CTGAAACCCA 8700 AACTGATATT GAAGGCATTA CCCGAATTAA ATATGAGATT CCTACACTAG ACAGGACAGG 8760 TAAACCTGAT GGTGGATTTA AGGAAATTTC AAGTATAAAA ACTGTTTATA ATCCTAAAAA 8820 ATTTTCTGAT GATAAAATAC TTCAAATGGC TCAAAATGCT GCTTCACAAG GATATTCAAA 8880 AGCCTCTAAA ATTGCTCAAA ATGAAAGAAC TAAATCAATA TCGGAAAGAA AAAATGTCAT 8940 TCAATTCTCA GAAACCTTTG ACGGAATCAA ATTTAGATCA TATTTTGATG TAAATACAGG 9000 AAGAATTACA AACATTCACC CAGAATAATT TAAAGGAAAA ATTATGAAAA ATAATATTTT 9060 TCTAAACTTA AATAAAAAAT CTATAAATAA CAACCATTTT GTTATTTCGA TTTTTTTTGA 9120 AACAATTTAC CAATTTGAAA CTAAAGATAC GCTTTTAGAG TGTTTTAAAA ATATTACAAC 9180 TACCGGACAT TTTGGAGTAA TAGGTGCTCA ATATGAAAAA ATAGATGCTA CCAGATGGAT 9240 TGGAGATTAT GAAGAGGTAA ATGGATTTGA GTATATTGAT AAAGCTCCTT CTATTTATTT 9300 TTCAGTTGGA GATGATTTCA ATCCTGAAGA ATTAATTATA CCTATTAATT TAGCATATCA 9360 TTACTTTAAT ATTGCAATAT CTGATTTCTT AATAGCTCAC CCTGAATATC AAAAAAAGTG 9420 TAAAGAAATA CAAAAAACAT ATTCTCAAAC AAACTGTAGC CTGCATGAAA CCTAAAATCC 9480 ATGCGTAAGG TGTGTGCTTC AGCACGCACG CGTTCCATGA TTTACGGCTC AATGCCGTCT 9540 GAAAAGCTCA CAATTTTTCA GACGGCATTT GTTATGCAAG TAAATATTCA GATTCCCTAT 9600 ATACTGCCCA GACGCGTGCG TGCTGAAGAC ACCCCCTACG CTTGCTGCAG AACTTTCGGG 9660 TAAAACCGGT GTGAGCATTA GCGCACCGTA TGCCAATGAG AACAGTCGCA TCCTGCTCAG 9720 CACCACGGAT ATCAGTTCGG AAAACGGCAA AATCAAAATT CAATCTTACG GTGACCAATA 9780 TTACTATGCG AGACAGAGCG AACTCTATAC CTTTGAACGC CGCAGCTACA AAACTGGCAA 9840 ATGGTACAAC CGCAAACACA TTACCGAAGT CAAAGAACAC AAAAACGCCA AGCCCGACGC 9900 AGTAAACCTC AGCGCATCCC AAGGCATCGA CATCAAATCT GGTGGCAGCA TCGACGCCTA 9960 CGCCACCGCA TTCGATGCCC CCAAAGGCAG CATTAACATC GAAGCCGGGC GGAAATTGAC 10020 ACTCTATGCC GTAGAAGAGC TCAACTACGA CAAACTAGAC AGCCAAAAAA GGCGCAGATT 10080 TCTCGGCATC AGCTACAGCA AAGCACACGA CACCACCACC CAAGTCATGA AAACCGCGCT 10140 GCCCTCAAGG GTAGTTGCAG AATCAGCCAA CCTCCAATCG GGCTGGGATA CCAAACTGCA 10200 AGGCACACAG TTTGAAACCA CACTGGGTGG CGCAACCATA CGCGCAGGCG TAGGTGAGCA 10260 GGCACGGGCA GATGCCAAGA TTATCCTCGA AGGGATCAAA AGCAGCATCC ACACAGAAAC 10320 CGTGAGCAGC AGCAAATCTA CTCTATGGCA AAAACAGGCA GGACGGGGCA GTAACATCGA 10380 AACCTTGCAA TTGCCGAGTT TCACCGGTCC CGTTGCGCCC GTACTGTCCG CACCCGGCGG 10440 TTACATTGTC GACATTCCGA AAGGCAATCT GAAAACCCAA ATCGAAACCC TCACCAAGCA 10500 GCCCGAGTAT GCTTATTTGA AACAACTTCA AGTTGCGAAA AACATCAACT GGAATCAGGT 10560 GCAGCTTGCT TACGATAAAT GGGACTACAA ACAGGAGGGC ATGACACCCG CAGCAGCAGC 10620 TGTCGTCGTT ATCGTCGTAA CCGTATTGAC CTACGGTGCA CTGTCCGCCC CGGCAGCCGC 10680 CGGAACGGCG GGCGCGGCAG GCGCAGGAGC GGGAGGAGCC GCAGCAGGAA CGGCAGCCGG 10740 AACTGGAGTA GCAGCAGGAA CGGCAGCCAC AACCGGAGTA GCAGCAGGCA CATCAGCTGC 10800 AGCTATCACC ACAGCCGCAG GCAAAGCCGC ACTGGCCAGT CTCGCCAGCC AAGCCGCAGT 10860 TTCCCTCATC AACAACAAAG GAGACATAAA CCATACCCTG AAAGAACTGG GCAAAAGCAG 10920 CACCGTCAGA CAGGCCGCCA CCGCCGCCGT AACCGCAGGC GTACTGCAGG GCATAAGCGG 10980 GCTGAACACC CAAGCAGCCG AAGCCGTCAG CAAACATTTT CACAGTCCCG CAGCAGGCAA 11040 ACTGACCGCT AACCTGATCA ACAGCACCGC TGCCGCAAGT GTCCATACCG CCATCAACGG 11100 CGGCAGCCTG AAAGACAACT TGGGCGATGC CGCACTGGGT GCGATAGTCA GTACCGTACA 11160 CGGAGAAGTA GCGAGCAAAA TCAAATTTAA TCTCAGCGAA GACTACATTG CCCACAAGAT 11220 AGCCCATGCC GTAGCAGGCT GTGCATCGGC GGTAGCAAAT AAAGGCAAAT GTCGGGACGG 11280 CGCAATCGGC GCGGCAGTCG GCGAGATGGT GGGAGAAACC CTGTTGGACG GACGCGATGT 11340 AGGCAAACTG TCACCCCAAG AACGCCAAAA AGTCATAGCC TACTCGCAGA TTATCGCAGG 11400 CAGCGCAGTG GCATTGGTTA AAGGGGATGT GAATACGGCG GTGAATGCGG CTACTGTGGC 11460 AGTGGAGAAT AATAGTCTTT TAGCTCGCAG GAGGGTAAAT ATACGTTGGA CTCCGCGACA 11520 AGAATTGGAA CATGAATATG CCATTCTTGA AATCCAGGCC ATTACCAATC AAATCCGAAG 11580 GCTGGATCCG AAATTTAACG GGATTGCTAT TCTGAGGACT CCTGGAGAGC CGTGGACAAG 11640 ACATGATGTA CAAACATACA GGCAATATTA TAATCAATTA AGGGAATCCA GAGGCTTTGC 11700 TGTTGAACCA ATTTATAGAA TCAGGATAAA CAACGGCAAT GAATTTAACC GTATCATGTC 11760 ATCAAAATAC CCTTATAATG AGCTTTATGT AGCCAATCCT AAATCGGCGA CGGGGTATTT 11820 TAGGGTAGAT TCGTATGATC CTGCGACAAG GGAAATTATT TCAAGAAAAT TTACCCAATT 11880 TTCTCAAATC CAAGAAAGTA CGGGGATTGG TTATATCAAG GAGGCTGTTA GAAAATATAG 11940 CCCTGGTACT GTCATTTCCA ATGTTCCAAG TACACCTACT ACGATAAGAG GAAGAAAGCT 12000 TGAAGGAAAA CTTATTTTAG AAGTTCCTGC TCAGGTCAAT CCAATTCCAC AATCTGTATT 12060 AAGGGCGGCA CAAGAAGAAA ATGTTATCAT TAGAGATACA ACAGGAAGGA TTTACAAATG 12120 AAGAAAGATA TTTTTTATTG TGAGCAGTGG TCTTATGGTT ATAAGAGACT TCATAAGCCT 12180 TTTTCTGAGA AACAAGCTGA GGAAAAACAT CTTAAAGGGG AGTTATATAC TGCCGTAATA 12240 GGTTCGGCGA CACAACCTGA ATATGTAATT ACCTTGCGAG AGGAAGTAGG TTTTTTTTCG 12300 GTAAATTTTT TCGATAAATT TGGAAGGGAT TATTTAACCC ATCAATTTCA AAAATATTCC 12360 AATTCGAATT ATTATTTTCT TTCTATGGCT GTATGGAGAG ATTATATAAC TTTGGAATCT 12420 CATGACTTAG CAGAAGGATA TACTTATTTC TTCAATGAAA ATACGGATGA TTGCTATGTT 12480 TTGAAACAAG ATTTTATTAA TAATGAGCGA TATGAAAAAA CAGAATTATA TTCCCAAAAA 12540 GATAAGGTAA TTCTATTTCC AAAGTTTGGT GAATATGATT TGGTGTTAAA TCCGGACATT 12600 ATTTAATTAA GTTTTAAGGC CGTCTGAAAA AAATTTCAAA CGGCTTTTAT TATTGGGTTT 12660 GGAATCTGAG GATAAAGCTG ATAAAAACCA GGAAATTATC AGATTGCTAT ATACGTATTG 12720 TTGTACAGAC TAAAGGCAGC AATCAAATCA CTATTGCTTA CCCACAAAAA TAAATTGATT 12780 ATATGGAATA ATCATGAATA AGAGAATGAA AATGTGTCCT GCTTGTCAAC AAGGCTATCT 12840 CTACCATTCG AAACCTAAAT ATCTTCATGA TGAAATTATT CTGTGTGATG AATGCGATGC 12900 AGTATGGCTC AAAGGTATGA ATATATTTTA TGGAGAATAT GAAAAAGATT TTTATTCTTA 12960 TGTTCCTTTC ATGGAATCCC AAGGTATAAC GAGTGAATGT ATTTGGGAAG GAGATTTGTT 13020 TGATCATCCA TATTATGAAG ATGAAAACTC AAATGATATG GATTGATGGA AATTTTAAGC 13080 CTGCGTAGGT ACGATTAGCC ATCAAACGGC GTAATCATAC GCAAGATTAT CAACAGAGAG 13140 GGCTGGCAGC GATATACCAC CCACAAGATT GCCCATGCCA TAGCGGGCTG TGCGGCAGCG 13200 GCGGCGAATA AGGGCAAGTG TCAGGATGGT GCGATAGGCG CTGCAGTCGG TGAGATTGTT 13260 GGTGAGGCTT TGGTTAAGAA TACTGATTTC AGTCGTATGA GTGCGACCGA AATCGAAAAA 13320 GCTAAAGCGA AGATTACTGC CTATTCAAAA CTGGTTGCCG GCACTGCGTC TGCCGTTGTA 13380 GGCGGGGATG TGAATACAGC GGCGAATGCG GCACAGATAG CGGTGGAGAA TAATACTTTG 13440 TATCCTAGAT GCGTTGGTGC AAAGTGTGAT GAATTTCAAA AGGAACAACA AAAATGGATA 13500 CGTGAAAATC CTGAAGAATA TCGAGAAGTT TTGCTTTTTC AGACAGGATT TATTCCAATT 13560 ATCGGTGATA TACAGAGTTT TGTACAAGCA CAGACCGCTG CCGATCACCT GTTTGCTTTG 13620 CTGGGTGTGG TTCCGGGTAT CGGTGAATCG ATACAGGCCT ATAAAGTAGC GAAAGCGGCA 13680 AAAAATTTAC AAGGCATGAA AAAAGCCTTG GACAAGGCAG CAACCGTTGC CACTGCACAG 13740 GGCTATGTCA GCAAAACCAA AATCAAAATC GGTCAAACTG AATTAAGGGT TACTGCAGCA 13800 ACTGACAAAC AATTGCTGAA AGCTATTGGC GAAGGAAGGG ACACGACAGG TAAAATGACC 13860 GAGCAGTTAT TTGACTCTTT AGCTAAACAA AATGGCTTCA GAGTGCTTTC GGGCGGCAAA 13920 TACGGCGGAA ATAACGGTTT TGATCATGTA TGGCAGGCTG CCGATGGTAG TGTCGTTTTG 13980 ATTGTAGAAA GTAAGCAGAT TAGGAACGGT ACGGTACAGC TGAATCCGAA TGGTGCGGGT 14040 GGATATACGC AAATGAGTGA GGATTGGATT AGACAAGTTT TAGATCAATT ACCCGATGGT 14100 AGTCCCGCTA AAGCTGCTGT CTTCAAAGCA AATAAGAACG GCACATTAAA AACAGCAATA 14160 GCAGGCGTTG ATCGTCAAAC AGGTAAGGCC GTTATTCTTC CTGTCAAAGT TCCTTCTAAA 14220 ACCAATATAA GGAGATAACA ATGGGGCACA ATATGATGAC CACCCAAAAA TGGTATGAGC 14280 ATATTACTAA TGTAATCATA GGCAATACTG CTAATTTCAA TAGCGGTTGC CTTGACTCTA 14340 TAGATTATGT AGATGAAAGA AAAGGCGTTC CGCTTGCAGC TATGCAACAT ATTTTCATGG 14400 ACGTTAGAGC TGCAGCTTCC CATGCCTATC TATTTGAACA TGATCTTAAG AAATTCAAGC 14460 AATATGCTTA TGTTGCAGGA AAGCTGGGGG TTTTGCTGAG TGTAAATTCT ACAGACCCTG 14520 AACCCTTCTT CTTTCCCTGT GACATGCTCA ACATTCAAAA TCCGATGTTT CTGATGCTGA 14580 TGAGCGACAG CCCACAGCTG CGTGAGTTTC TGGTGCGCAA TATCGACAAC ATCGCCAACG 14640 ATACAGAAGC CTTTATAAAC CGCTACGACC TCAACCGGCA TATGATTTAC AATACTCTGC 14700 TGATGGTGGA GGGTAAGCAG CTTGATCGGT TGAAACAACG TAGCGAGAAA GTCTTGGCGC 14760 ATCCCACCCC TAGCAAATGG CTGCAAAAGC GGTTGTACGA TTACCGCTTC TTCCTCGCTT 14820 TCGCCGAACA GGATGCCGAG GCAATGAAAG CCGCCTTAGA GCCGCTTTTC GATAAAAAAA 14880 CCGCGCGTAT GGCTGCCAAA GAAACATTGT CCTATTTCGA TTTCTACCTG CAGCCGCAAA 14940 TCGTTACCTA CGCCAAAATC GCATCCATGC ACGGTTTCGA TTTGGGCATA GATCAAGAAA 15000 TCTCACCGAG GGATTTGATT GTTTACGATC CGCTGCCGGC AGACGAATAT CAAGACATCT 15060 TCGATTTTAT GAAACAGTAT GACTTGTCTT ACCCGTATGA ATATCTGCAG GATTGGATAG 15120 ATTACTATAC GTTCAAAACC GATAAGCTGG TATTTGGTAA CGCGAAGCGA GAGTGAGCCG 15180 TAAAACTCTG AGCTCCTGTT TTATAGATTA CAACTTTAGG CCGTCTTAAA GCTGAAAGAT 15240 TTTCGAAAGC TATAAATTGA AGCCCTTCCA CAGTACATAG ATCTGTGTTG TGGCGGGGCT 15300 TTACCACGCT GATTGCCGGA GAAGAACTCA ACCTGCTGGC AAAACAAGGC ATGAGATCTT 15360 TGCAATAACA TGAGTTGAGA CCTTTGCAAA AAAGCCCTTC CCCGACATCC GAAACCCAAA 15420 CACAGGATTT CGGCTGTTTT CGTACCAAAT ACCTCCTAAT TTTACCCAAA TACCCCCTTA 15480 ATCCTCCTCG GACACCCGAT AATCAGGCAT CCGGGCTGCC TTTTAGGCGG CAGCGGGCGC 15540 ATTTAGCCTG TTGGCCGCTT TCAACAGGTT CAAACACATC GCCTTCAGGT GGCTTTGCGC 15600 ACTCACTTTG TCATTTCCAA 15620 580 acides amin,s acide amin, single linear peptide Protein 1..580 37 Met Lys Phe Phe Pro Ala Pro Cys Leu Leu Val Ile Leu Ala Val Ile 1 5 10 15 Pro Leu Lys Thr Leu Ala Ala Asp Glu Asn Asp Ala Glu Leu Ile Arg 20 25 30 Ser Met Gln Arg Gln Gln His Ile Asp Ala Glu Leu Leu Thr Asp Ala 35 40 45 Asn Val Arg Phe Glu Gln Pro Leu Glu Lys Asn Asn Tyr Val Leu Ser 50 55 60 Glu Asp Glu Thr Pro Cys Thr Arg Val Asn Tyr Ile Ser Leu Asp Asp 65 70 75 80 Lys Thr Ala Arg Lys Phe Ser Phe Leu Pro Ser Val Leu Met Lys Glu 85 90 95 Thr Ala Phe Lys Thr Gly Met Cys Leu Gly Ser Asn Asn Leu Ser Arg 100 105 110 Leu Gln Lys Ala Ala Gln Gln Ile Leu Ile Val Arg Gly Tyr Leu Thr 115 120 125 Ser Gln Ala Ile Ile Gln Pro Gln Asn Met Asp Ser Gly Ile Leu Lys 130 135 140 Leu Arg Val Ser Ala Gly Glu Ile Gly Asp Ile Arg Tyr Glu Glu Lys 145 150 155 160 Arg Asp Gly Lys Ser Ala Glu Gly Ser Ile Ser Ala Phe Asn Asn Lys 165 170 175 Phe Pro Leu Tyr Arg Asn Lys Ile Leu Asn Leu Arg Asp Val Glu Gln 180 185 190 Gly Leu Glu Asn Leu Arg Arg Leu Pro Ser Val Lys Thr Asp Ile Gln 195 200 205 Ile Ile Pro Ser Glu Glu Glu Gly Lys Ser Asp Leu Gln Ile Lys Trp 210 215 220 Gln Gln Asn Lys Pro Ile Arg Phe Ser Ile Gly Ile Asp Asp Ala Gly 225 230 235 240 Gly Lys Thr Thr Gly Lys Tyr Gln Gly Asn Val Ala Leu Ser Phe Asp 245 250 255 Asn Pro Leu Gly Leu Ser Asp Leu Phe Tyr Val Ser Tyr Gly Arg Gly 260 265 270 Leu Val His Lys Thr Asp Leu Thr Asp Ala Thr Gly Thr Glu Thr Glu 275 280 285 Ser Gly Ser Arg Ser Tyr Ser Val His Tyr Ser Val Pro Val Lys Lys 290 295 300 Trp Leu Phe Ser Phe Asn His Asn Gly His Arg Tyr His Glu Ala Thr 305 310 315 320 Glu Gly Tyr Ser Val Asn Tyr Asp Tyr Asn Gly Lys Gln Tyr Gln Ser 325 330 335 Ser Leu Ala Ala Glu Arg Met Leu Trp Arg Asn Arg Phe His Lys Thr 340 345 350 Ser Val Gly Met Lys Leu Trp Thr Arg Gln Thr Tyr Lys Tyr Ile Asp 355 360 365 Asp Ala Glu Ile Glu Val Gln Arg Arg Arg Ser Ala Gly Trp Glu Ala 370 375 380 Glu Leu Arg His Arg Ala Tyr Leu Asn Arg Trp Gln Leu Asp Gly Lys 385 390 395 400 Leu Ser Tyr Lys Arg Gly Thr Gly Met Arg Gln Ser Met Pro Ala Pro 405 410 415 Glu Glu Asn Gly Gly Gly Thr Ile Pro Gly Thr Ser Arg Met Lys Ile 420 425 430 Ile Thr Ala Gly Leu Asp Ala Ala Ala Pro Phe Met Leu Gly Lys Gln 435 440 445 Gln Phe Phe Tyr Ala Thr Ala Ile Gln Ala Gln Trp Asn Lys Thr Pro 450 455 460 Leu Val Ala Gln Asp Lys Leu Ser Ile Gly Ser Arg Tyr Thr Val Arg 465 470 475 480 Gly Phe Asp Gly Glu Gln Ser Leu Phe Gly Glu Arg Gly Phe Tyr Trp 485 490 495 Gln Asn Thr Leu Thr Trp Tyr Phe His Pro Asn His Gln Phe Tyr Leu 500 505 510 Gly Ala Asp Tyr Gly Arg Val Ser Gly Glu Ser Ala Gln Tyr Val Ser 515 520 525 Gly Lys Gln Leu Met Gly Ala Val Val Gly Phe Arg Gly Gly His Lys 530 535 540 Val Gly Gly Met Phe Ala Tyr Asp Leu Phe Ala Gly Lys Pro Leu His 545 550 555 560 Lys Pro Lys Gly Phe Gln Thr Thr Asn Thr Val Tyr Gly Phe Asn Leu 565 570 575 Asn Tyr Ser Phe 580 1981 acides amin,s acide amin, single linear peptide Peptide 1..1981 38 Met Asn Lys Gly Leu His Arg Ile Ile Phe Ser Lys Lys His Ser Thr 1 5 10 15 Met Val Ala Val Ala Glu Thr Ala Asn Ser Gln Gly Lys Gly Lys Gln 20 25 30 Ala Gly Ser Ser Val Ser Val Ser Leu Lys Thr Ser Gly Asp Leu Cys 35 40 45 Gly Lys Leu Lys Thr Thr Leu Lys Thr Leu Val Cys Ser Leu Val Ser 50 55 60 Leu Ser Met Val Leu Pro Ala His Ala Gln Ile Thr Thr Asp Lys Ser 65 70 75 80 Ala Pro Lys Asn Gln Gln Val Val Ile Leu Lys Thr Asn Thr Gly Ala 85 90 95 Pro Leu Val Asn Ile Gln Thr Pro Asn Gly Arg Gly Leu Ser His Asn 100 105 110 Arg Tyr Thr Gln Phe Asp Val Asp Asn Lys Gly Ala Val Leu Asn Asn 115 120 125 Asp Arg Asn Asn Asn Pro Phe Leu Val Lys Gly Ser Ala Gln Leu Ile 130 135 140 Leu Asn Glu Val Arg Gly Thr Ala Ser Lys Leu Asn Gly Ile Val Thr 145 150 155 160 Val Gly Gly Gln Lys Ala Asp Val Ile Ile Ala Asn Pro Asn Gly Ile 165 170 175 Thr Val Asn Gly Gly Gly Phe Lys Asn Val Gly Arg Gly Ile Leu Thr 180 185 190 Ile Gly Ala Pro Gln Ile Gly Lys Asp Gly Ala Leu Thr Gly Phe Asp 195 200 205 Val Arg Gln Gly Thr Leu Thr Val Gly Ala Ala Gly Trp Asn Asp Lys 210 215 220 Gly Gly Ala Asp Tyr Thr Gly Val Leu Ala Arg Ala Val Ala Leu Gln 225 230 235 240 Gly Lys Leu Gln Gly Lys Asn Leu Ala Val Ser Thr Gly Pro Gln Lys 245 250 255 Val Asp Tyr Ala Ser Gly Glu Ile Ser Ala Gly Thr Ala Ala Gly Thr 260 265 270 Lys Pro Thr Ile Ala Leu Asp Thr Ala Ala Leu Gly Gly Met Tyr Ala 275 280 285 Asp Ser Ile Thr Leu Ile Ala Asn Glu Lys Gly Val Gly Val Lys Asn 290 295 300 Ala Gly Thr Leu Glu Ala Ala Lys Gln Leu Ile Val Thr Ser Ser Gly 305 310 315 320 Arg Ile Glu Asn Ser Gly Arg Ile Ala Thr Thr Ala Asp Gly Thr Glu 325 330 335 Ala Ser Pro Thr Tyr Leu Ser Ile Glu Thr Thr Glu Lys Gly Ala Ala 340 345 350 Gly Thr Phe Ile Ser Asn Gly Gly Arg Ile Glu Ser Lys Gly Leu Leu 355 360 365 Val Ile Glu Thr Gly Glu Asp Ile Ser Leu Arg Asn Gly Ala Val Val 370 375 380 Gln Asn Asn Gly Ser Arg Pro Ala Thr Thr Val Leu Asn Ala Gly His 385 390 395 400 Asn Leu Val Ile Glu Ser Lys Thr Asn Val Asn Asn Ala Lys Gly Ser 405 410 415 Ala Asn Leu Ser Ala Gly Gly Arg Thr Thr Ile Asn Asp Ala Thr Ile 420 425 430 Gln Ala Gly Ser Ser Val Tyr Ser Ser Thr Lys Gly Asp Thr Glu Leu 435 440 445 Gly Glu Asn Thr Arg Ile Ile Ala Glu Asn Val Thr Val Leu Ser Asn 450 455 460 Gly Ser Ile Gly Ser Ala Ala Val Ile Glu Ala Lys Asp Thr Ala His 465 470 475 480 Ile Glu Ser Gly Lys Pro Leu Ser Leu Glu Thr Ser Thr Val Ala Ser 485 490 495 Asn Ile Arg Leu Asn Asn Gly Asn Ile Lys Gly Gly Lys Gln Leu Ala 500 505 510 Leu Leu Ala Asp Asp Asn Ile Thr Ala Lys Thr Thr Asn Leu Asn Thr 515 520 525 Pro Gly Asn Leu Tyr Val His Thr Gly Lys Asp Leu Asn Leu Asn Val 530 535 540 Asp Lys Asp Leu Ser Ala Ala Ser Ile His Leu Lys Ser Asp Asn Ala 545 550 555 560 Ala His Ile Thr Gly Thr Ser Lys Thr Leu Thr Ala Ser Lys Asp Met 565 570 575 Gly Val Glu Ala Gly Leu Leu Asn Val Thr Asn Thr Asn Leu Arg Thr 580 585 590 Asn Ser Gly Asn Leu His Ile Gln Ala Ala Lys Gly Asn Ile Gln Leu 595 600 605 Arg Asn Thr Lys Leu Asn Ala Ala Lys Ala Leu Glu Thr Thr Ala Leu 610 615 620 Gln Gly Asn Ile Val Ser Asp Gly Leu His Ala Val Ser Ala Asp Gly 625 630 635 640 His Val Ser Leu Leu Ala Asn Gly Asn Ala Asp Phe Thr Gly His Asn 645 650 655 Thr Leu Thr Ala Lys Ala Asp Val Asn Ala Gly Ser Val Gly Lys Gly 660 665 670 Arg Leu Lys Ala Asp Asn Thr Asn Ile Thr Ser Ser Ser Gly Asp Ile 675 680 685 Thr Leu Val Ala Gly Asn Gly Ile Gln Leu Gly Asp Gly Lys Gln Arg 690 695 700 Asn Ser Ile Asn Gly Lys His Ile Ser Ile Lys Asn Asn Gly Gly Asn 705 710 715 720 Ala Asp Leu Lys Asn Leu Asn Val His Ala Lys Ser Gly Ala Leu Asn 725 730 735 Ile His Ser Asp Arg Ala Leu Ser Ile Glu Asn Thr Lys Leu Glu Ser 740 745 750 Thr His Asn Thr His Leu Asn Ala Gln His Glu Arg Val Thr Leu Asn 755 760 765 Gln Val Asp Ala Tyr Ala His Arg His Leu Ser Ile Thr Gly Ser Gln 770 775 780 Ile Trp Gln Asn Asp Lys Leu Pro Ser Ala Asn Lys Leu Val Ala Asn 785 790 795 800 Gly Val Leu Ala Leu Asn Ala Arg Tyr Ser Gln Ile Ala Asp Asn Thr 805 810 815 Thr Leu Arg Ala Gly Ala Ile Asn Leu Thr Ala Gly Thr Ala Leu Val 820 825 830 Lys Arg Gly Asn Ile Asn Trp Ser Thr Val Ser Thr Lys Thr Leu Glu 835 840 845 Asp Asn Ala Glu Leu Lys Pro Leu Ala Gly Arg Leu Asn Ile Glu Ala 850 855 860 Gly Ser Gly Thr Leu Thr Ile Glu Pro Ala Asn Arg Ile Ser Ala His 865 870 875 880 Thr Asp Leu Ser Ile Lys Thr Gly Gly Lys Leu Leu Leu Ser Ala Lys 885 890 895 Gly Gly Asn Ala Gly Ala Pro Ser Ala Gln Val Ser Ser Leu Glu Ala 900 905 910 Lys Gly Asn Ile Arg Leu Val Thr Gly Glu Thr Asp Leu Arg Gly Ser 915 920 925 Lys Ile Thr Ala Gly Lys Asn Leu Val Val Ala Thr Thr Lys Gly Lys 930 935 940 Leu Asn Ile Glu Ala Val Asn Asn Ser Phe Ser Asn Tyr Phe Pro Thr 945 950 955 960 Gln Lys Ala Ala Glu Leu Asn Gln Lys Ser Lys Glu Leu Glu Gln Gln 965 970 975 Ile Ala Gln Leu Lys Lys Ser Ser Pro Lys Ser Lys Leu Ile Pro Thr 980 985 990 Leu Gln Glu Glu Arg Asp Arg Leu Ala Phe Tyr Ile Gln Ala Ile Asn 995 1000 1005 Lys Glu Val Lys Gly Lys Lys Pro Lys Gly Lys Glu Tyr Leu Gln Ala 1010 1015 1020 Lys Leu Ser Ala Gln Asn Ile Asp Leu Ile Ser Ala Gln Gly Ile Glu 1025 1030 1035 1040 Ile Ser Gly Ser Asp Ile Thr Ala Ser Lys Lys Leu Asn Leu His Ala 1045 1050 1055 Ala Gly Val Leu Pro Lys Ala Ala Asp Ser Glu Ala Ala Ala Ile Leu 1060 1065 1070 Ile Asp Gly Ile Thr Asp Gln Tyr Glu Ile Gly Lys Pro Thr Tyr Lys 1075 1080 1085 Ser His Tyr Asp Lys Ala Ala Leu Asn Lys Pro Ser Arg Leu Thr Gly 1090 1095 1100 Arg Thr Gly Val Ser Ile His Ala Ala Ala Ala Leu Asp Asp Ala Arg 1105 1110 1115 1120 Ile Ile Ile Gly Ala Ser Glu Ile Lys Ala Pro Ser Gly Ser Ile Asp 1125 1130 1135 Ile Lys Ala His Ser Asp Ile Val Leu Glu Ala Gly Gln Asn Asp Ala 1140 1145 1150 Tyr Thr Phe Leu Lys Thr Lys Gly Lys Ser Gly Lys Ile Ile Arg Lys 1155 1160 1165 Thr Lys Phe Thr Ser Thr Arg Asp His Leu Ile Met Pro Ala Pro Val 1170 1175 1180 Glu Leu Thr Ala Asn Gly Ile Thr Leu Gln Ala Gly Gly Asn Ile Glu 1185 1190 1195 1200 Ala Asn Thr Thr Arg Phe Asn Ala Pro Ala Gly Lys Val Thr Leu Val 1205 1210 1215 Ala Gly Glu Glu Leu Gln Leu Leu Ala Glu Glu Gly Ile His Lys His 1220 1225 1230 Glu Leu Asp Val Gln Lys Ser Arg Arg Phe Ile Gly Ile Lys Val Gly 1235 1240 1245 Lys Ser Asn Tyr Ser Lys Asn Glu Leu Asn Glu Thr Lys Leu Pro Val 1250 1255 1260 Arg Val Val Ala Gln Thr Ala Ala Thr Arg Ser Gly Trp Asp Thr Val 1265 1270 1275 1280 Leu Glu Gly Thr Glu Phe Lys Thr Thr Leu Ala Gly Ala Asp Ile Gln 1285 1290 1295 Ala Gly Val Gly Glu Lys Ala Arg Val Asp Ala Lys Ile Ile Leu Lys 1300 1305 1310 Gly Ile Val Asn Arg Ile Gln Ser Glu Glu Lys Leu Glu Thr Asn Ser 1315 1320 1325 Thr Val Trp Gln Lys Gln Ala Gly Arg Gly Ser Thr Ile Glu Thr Leu 1330 1335 1340 Lys Leu Pro Ser Phe Glu Ser Pro Thr Pro Pro Lys Leu Ser Ala Pro 1345 1350 1355 1360 Gly Gly Tyr Ile Val Asp Ile Pro Lys Gly Asn Leu Lys Thr Glu Ile 1365 1370 1375 Glu Lys Leu Ser Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 1380 1385 1390 Val Ala Lys Asn Ile Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Arg 1395 1400 1405 Trp Asp Tyr Lys Gln Glu Gly Leu Thr Glu Ala Gly Ala Ala Ile Ile 1410 1415 1420 Ala Leu Ala Val Thr Val Val Thr Ser Gly Ala Gly Thr Gly Ala Val 1425 1430 1435 1440 Leu Gly Leu Asn Gly Ala Ala Ala Ala Ala Thr Asp Ala Ala Phe Ala 1445 1450 1455 Ser Leu Ala Ser Gln Ala Ser Val Ser Phe Ile Asn Asn Lys Gly Asp 1460 1465 1470 Val Gly Lys Thr Leu Lys Glu Leu Gly Arg Ser Ser Thr Val Lys Asn 1475 1480 1485 Leu Val Val Ala Ala Ala Thr Ala Gly Val Ala Asp Lys Ile Gly Ala 1490 1495 1500 Ser Ala Leu Asn Asn Val Ser Asp Lys Gln Trp Ile Asn Asn Leu Thr 1505 1510 1515 1520 Val Asn Leu Ala Asn Ala Gly Ser Ala Ala Leu Ile Asn Thr Ala Val 1525 1530 1535 Asn Gly Gly Ser Leu Lys Asp Asn Leu Glu Ala Asn Ile Leu Ala Ala 1540 1545 1550 Leu Val Asn Thr Ala His Gly Glu Ala Ala Ser Lys Ile Lys Gln Leu 1555 1560 1565 Asp Gln His Tyr Ile Val His Lys Ile Ala His Ala Ile Ala Gly Cys 1570 1575 1580 Ala Ala Ala Ala Ala Asn Lys Gly Lys Cys Gln Asp Gly Ala Ile Gly 1585 1590 1595 1600 Ala Ala Val Gly Glu Ile Val Gly Glu Ala Leu Thr Asn Gly Lys Asn 1605 1610 1615 Pro Asp Thr Leu Thr Ala Lys Glu Arg Glu Gln Ile Leu Ala Tyr Ser 1620 1625 1630 Lys Leu Val Ala Gly Thr Val Ser Gly Val Val Gly Gly Asp Val Asn 1635 1640 1645 Ala Ala Ala Asn Ala Ala Glu Val Ala Val Lys Asn Asn Gln Leu Ser 1650 1655 1660 Asp Lys Glu Gly Arg Glu Phe Asp Asn Glu Met Thr Ala Cys Ala Lys 1665 1670 1675 1680 Gln Asn Asn Pro Gln Leu Cys Arg Lys Asn Thr Val Lys Lys Tyr Gln 1685 1690 1695 Asn Val Ala Asp Lys Arg Leu Ala Ala Ser Ile Ala Ile Cys Thr Asp 1700 1705 1710 Ile Ser Arg Ser Thr Glu Cys Arg Thr Ile Arg Lys Gln His Leu Ile 1715 1720 1725 Asp Ser Arg Ser Leu His Ser Ser Trp Glu Ala Gly Leu Ile Gly Lys 1730 1735 1740 Asp Asp Glu Trp Tyr Lys Leu Phe Ser Lys Ser Tyr Thr Gln Ala Asp 1745 1750 1755 1760 Leu Ala Leu Gln Ser Tyr His Leu Asn Thr Ala Ala Lys Ser Trp Leu 1765 1770 1775 Gln Ser Gly Asn Thr Lys Pro Leu Ser Glu Trp Met Ser Asp Gln Gly 1780 1785 1790 Tyr Thr Leu Ile Ser Gly Val Asn Pro Arg Phe Ile Pro Ile Pro Arg 1795 1800 1805 Gly Phe Val Lys Gln Asn Thr Pro Ile Thr Asn Val Lys Tyr Pro Glu 1810 1815 1820 Gly Ile Ser Phe Asp Thr Asn Leu Lys Arg His Leu Ala Asn Ala Asp 1825 1830 1835 1840 Gly Phe Ser Gln Glu Gln Gly Ile Lys Gly Ala His Asn Arg Thr Asn 1845 1850 1855 Phe Met Ala Glu Leu Asn Ser Arg Gly Gly Arg Val Lys Ser Glu Thr 1860 1865 1870 Gln Thr Asp Ile Glu Gly Ile Thr Arg Ile Lys Tyr Glu Ile Pro Thr 1875 1880 1885 Leu Asp Arg Thr Gly Lys Pro Asp Gly Gly Phe Lys Glu Ile Ser Ser 1890 1895 1900 Ile Lys Thr Val Tyr Asn Pro Lys Lys Phe Ser Asp Asp Lys Ile Leu 1905 1910 1915 1920 Gln Met Ala Gln Asn Ala Ala Ser Gln Gly Tyr Ser Lys Ala Ser Lys 1925 1930 1935 Ile Ala Gln Asn Glu Arg Thr Lys Ser Ile Ser Glu Arg Lys Asn Val 1940 1945 1950 Ile Gln Phe Ser Glu Thr Phe Asp Gly Ile Lys Phe Arg Ser Tyr Phe 1955 1960 1965 Asp Val Asn Thr Gly Arg Ile Thr Asn Ile His Pro Glu 1970 1975 1980 143 acides amin,s acide amin, single linear peptide Peptide 1..143 39 Met Lys Asn Asn Ile Phe Leu Asn Leu Asn Lys Lys Ser Ile Asn Asn 1 5 10 15 Asn His Phe Val Ile Ser Ile Phe Phe Glu Thr Ile Tyr Gln Phe Glu 20 25 30 Thr Lys Asp Thr Leu Leu Glu Cys Phe Lys Asn Ile Thr Thr Thr Gly 35 40 45 His Phe Gly Val Ile Gly Ala Gln Tyr Glu Lys Ile Asp Ala Thr Arg 50 55 60 Trp Ile Gly Asp Tyr Glu Glu Val Asn Gly Phe Glu Tyr Ile Asp Lys 65 70 75 80 Ala Pro Ser Ile Tyr Phe Ser Val Gly Asp Asp Phe Asn Pro Glu Glu 85 90 95 Leu Ile Ile Pro Ile Asn Leu Ala Tyr His Tyr Phe Asn Ile Ala Ile 100 105 110 Ser Asp Phe Leu Ile Ala His Pro Glu Tyr Gln Lys Lys Cys Lys Glu 115 120 125 Ile Gln Lys Thr Tyr Ser Gln Thr Asn Cys Ser Leu His Glu Thr 130 135 140 833 acides amin,s acide amin, single linear peptide Peptide 1..833 40 Val Leu Lys Thr Pro Pro Thr Leu Ala Ala Glu Leu Ser Gly Lys Thr 1 5 10 15 Gly Val Ser Ile Ser Ala Pro Tyr Ala Asn Glu Asn Ser Arg Ile Leu 20 25 30 Leu Ser Thr Thr Asp Ile Ser Ser Glu Asn Gly Lys Ile Lys Ile Gln 35 40 45 Ser Tyr Gly Asp Gln Tyr Tyr Tyr Ala Arg Gln Ser Glu Leu Tyr Thr 50 55 60 Phe Glu Arg Arg Ser Tyr Lys Thr Gly Lys Trp Tyr Asn Arg Lys His 65 70 75 80 Ile Thr Glu Val Lys Glu His Lys Asn Ala Lys Pro Asp Ala Val Asn 85 90 95 Leu Ser Ala Ser Gln Gly Ile Asp Ile Lys Ser Gly Gly Ser Ile Asp 100 105 110 Ala Tyr Ala Thr Ala Phe Asp Ala Pro Lys Gly Ser Ile Asn Ile Glu 115 120 125 Ala Gly Arg Lys Leu Thr Leu Tyr Ala Val Glu Glu Leu Asn Tyr Asp 130 135 140 Lys Leu Asp Ser Gln Lys Arg Arg Arg Phe Leu Gly Ile Ser Tyr Ser 145 150 155 160 Lys Ala His Asp Thr Thr Thr Gln Val Met Lys Thr Ala Leu Pro Ser 165 170 175 Arg Val Val Ala Glu Ser Ala Asn Leu Gln Ser Gly Trp Asp Thr Lys 180 185 190 Leu Gln Gly Thr Gln Phe Glu Thr Thr Leu Gly Gly Ala Thr Ile Arg 195 200 205 Ala Gly Val Gly Glu Gln Ala Arg Ala Asp Ala Lys Ile Ile Leu Glu 210 215 220 Gly Ile Lys Ser Ser Ile His Thr Glu Thr Val Ser Ser Ser Lys Ser 225 230 235 240 Thr Leu Trp Gln Lys Gln Ala Gly Arg Gly Ser Asn Ile Glu Thr Leu 245 250 255 Gln Leu Pro Ser Phe Thr Gly Pro Val Ala Pro Val Leu Ser Ala Pro 260 265 270 Gly Gly Tyr Ile Val Asp Ile Pro Lys Gly Asn Leu Lys Thr Gln Ile 275 280 285 Glu Thr Leu Thr Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 290 295 300 Val Ala Lys Asn Ile Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Lys 305 310 315 320 Trp Asp Tyr Lys Gln Glu Gly Met Thr Pro Ala Ala Ala Ala Val Val 325 330 335 Val Ile Val Val Thr Val Leu Thr Tyr Gly Ala Leu Ser Ala Pro Ala 340 345 350 Ala Ala Gly Thr Ala Gly Ala Ala Gly Ala Gly Ala Gly Gly Ala Ala 355 360 365 Ala Gly Thr Ala Ala Gly Thr Gly Val Ala Ala Gly Thr Ala Ala Thr 370 375 380 Thr Gly Val Ala Ala Gly Thr Ser Ala Ala Ala Ile Thr Thr Ala Ala 385 390 395 400 Gly Lys Ala Ala Leu Ala Ser Leu Ala Ser Gln Ala Ala Val Ser Leu 405 410 415 Ile Asn Asn Lys Gly Asp Ile Asn His Thr Leu Lys Glu Leu Gly Lys 420 425 430 Ser Ser Thr Val Arg Gln Ala Ala Thr Ala Ala Val Thr Ala Gly Val 435 440 445 Leu Gln Gly Ile Ser Gly Leu Asn Thr Gln Ala Ala Glu Ala Val Ser 450 455 460 Lys His Phe His Ser Pro Ala Ala Gly Lys Leu Thr Ala Asn Leu Ile 465 470 475 480 Asn Ser Thr Ala Ala Ala Ser Val His Thr Ala Ile Asn Gly Gly Ser 485 490 495 Leu Lys Asp Asn Leu Gly Asp Ala Ala Leu Gly Ala Ile Val Ser Thr 500 505 510 Val His Gly Glu Val Ala Ser Lys Ile Lys Phe Asn Leu Ser Glu Asp 515 520 525 Tyr Ile Ala His Lys Ile Ala His Ala Val Ala Gly Cys Ala Ser Ala 530 535 540 Val Ala Asn Lys Gly Lys Cys Arg Asp Gly Ala Ile Gly Ala Ala Val 545 550 555 560 Gly Glu Met Val Gly Glu Thr Leu Leu Asp Gly Arg Asp Val Gly Lys 565 570 575 Leu Ser Pro Gln Glu Arg Gln Lys Val Ile Ala Tyr Ser Gln Ile Ile 580 585 590 Ala Gly Ser Ala Val Ala Leu Val Lys Gly Asp Val Asn Thr Ala Val 595 600 605 Asn Ala Ala Thr Val Ala Val Glu Asn Asn Ser Leu Leu Ala Arg Arg 610 615 620 Arg Val Asn Ile Arg Trp Thr Pro Arg Gln Glu Leu Glu His Glu Tyr 625 630 635 640 Ala Ile Leu Glu Ile Gln Ala Ile Thr Asn Gln Ile Arg Arg Leu Asp 645 650 655 Pro Lys Phe Asn Gly Ile Ala Ile Leu Arg Thr Pro Gly Glu Pro Trp 660 665 670 Thr Arg His Asp Val Gln Thr Tyr Arg Gln Tyr Tyr Asn Gln Leu Arg 675 680 685 Glu Ser Arg Gly Phe Ala Val Glu Pro Ile Tyr Arg Ile Arg Ile Asn 690 695 700 Asn Gly Asn Glu Phe Asn Arg Ile Met Ser Ser Lys Tyr Pro Tyr Asn 705 710 715 720 Glu Leu Tyr Val Ala Asn Pro Lys Ser Ala Thr Gly Tyr Phe Arg Val 725 730 735 Asp Ser Tyr Asp Pro Ala Thr Arg Glu Ile Ile Ser Arg Lys Phe Thr 740 745 750 Gln Phe Ser Gln Ile Gln Glu Ser Thr Gly Ile Gly Tyr Ile Lys Glu 755 760 765 Ala Val Arg Lys Tyr Ser Pro Gly Thr Val Ile Ser Asn Val Pro Ser 770 775 780 Thr Pro Thr Thr Ile Arg Gly Arg Lys Leu Glu Gly Lys Leu Ile Leu 785 790 795 800 Glu Val Pro Ala Gln Val Asn Pro Ile Pro Gln Ser Val Leu Arg Ala 805 810 815 Ala Gln Glu Glu Asn Val Ile Ile Arg Asp Thr Thr Gly Arg Ile Tyr 820 825 830 Lys 664 acides amin,s acide amin, linear protein 41 Val leu Lys Thr Pro Pro Thr Leu Ala Ala Glu leu Ser Gly Lys Thr 1 5 10 15 Gly Val Ser Ile Ser Ala Pro Tyr Ala Asn Glu Asn Ser Arg Ile Leu 20 25 30 Leu Ser Thr Thr Asp Ile Ser Ser Glu Asn Gly Lys Ile Lys Ile Gln 35 40 45 Ser Tyr Gly Asp Gln Tyr Tyr Tyr Ala Arg Gln Ser Glu Leu Tyr Thr 50 55 60 Phe Glu Arg Arg Ser Tyr Lys Thr Gly Lys Trp Tyr Asn Arg Lys His 65 70 75 80 Ile Thr Glu Val Lys Glu His Lys Asn Ala Lys pro Asp Ala Val Asn 85 90 95 Leu Ser Ala Ser Gln Gly Ile Asp Ile Lys Ser Gly Gly Ser Ile Asp 100105110 Ala Tyr Ala Thr Ala Phe Asp Ala Pro Lys Gly Ser Ile Asn Ile Glu 115120125 Ala GlyArg Lys Leu Thr leu Tyr Ala Val Glu Glu Leu Asn Tyr Asp 130135 140 Lys leu Asp Ser Gln Lys Arg Arg Arg Phe Leu Gly Ile Ser Tyr Ser 145150155160 Lys Ala His Asp Thr Thr Thr Gln Val Met Lys Thr Ala Leu Pro Ser 165 170 175 Arg Val Val Ala Glu Ser Ala Asn Leu Gln Ser Gly Trp Asp Thr Lys 180 185 190 Leu Gln Gly Thr Gln Phe Glu Thr Thr Leu Gly Gly Ala Thr Ile Arg 195 200 205 Ala Gly Val Gly Glu Gln Ala Arg Ala Asp Ala Lys Ile Ile Leu Glu 210 215 220 Gly Ile Lys Ser Ser Ile His Thr Glu Thr Val Ser Ser Ser Lys Ser 225 230 235 240 Thr Leu Trp Gln Lys Gln Ala Gly Arg Gly Ser Asn Ile Glu Thr Leu 245 250 255 Gln Leu Pro Ser Phe Thr Gly Pro Val Ala Pro Val Leu Ser Ala Pro 260 265 270 Gly Gly Tyr Ile Val Asp Ile Pro Lys Gly Asn Leu Lys Thr Gln Ile 275 280 285 Glu Thr Leu Thr Lys Gln Pro Glu Tyr Ala Tyr Leu Lys Gln Leu Gln 290 295 300 Val Ala Lys Asn Ile Asn Trp Asn Gln Val Gln Leu Ala Tyr Asp Lys 305 310 315 320 Trp Asp Tyr Lys Gln Glu Gly Met Thr Pro Ala Ala Ala Ala Val Val 325 330 335 Val Ile Val Val Thr Val Leu Thr Tyr Gly Ala Leu Ser Ala Pro Ala 340 345 350 Ala Ala Gly Thr Ala Gly Ala Ala Gly Ala Gly Ala Gly Gly Ala Ala 355 360 365 Ala Gly Thr Ala Ala Gly Thr Gly Val Ala Ala Gly Thr Ala Ala Thr 370 375 380 Thr Gly Val Ala Ala Gly Thr Ser Ala Ala Ala Ile Thr Thr Ala Ala 385 390 395 400 Gly Lys Ala Ala Leu Ala Ser Leu Ala Ser Gln Ala Ala Val Ser Leu 405 410 415 Ile Asn Asn Lys Gly Asp Ile Asn His Thr Leu Lys Glu Leu Gly Lys 420 425 430 Ser Ser Thr Val Arg Gln Ala Ala Thr Ala Ala Val Thr Ala Gly Val 435 440 445 Leu Gln Gly Ile Ser Gly Leu Asn Thr Gln Ala Ala Glu Ala Val Ser 450 455 460 Lys His Phe His Ser Pro Ala Ala Gly Lys Leu Thr Ala Asn Leu Ile 465 470 475 480 Asn Ser Thr Ala Ala Ala Ser Val His Thr Ala Ile Asn Gly Gly Ser 485 490 495 Leu Lys Asp Asn Leu Gly Asp Ala Ala Leu Gly Ala Ile Val Ser Thr 500 505 510 Val His Gly Glu Val Ala Ser Lys Ile Lys Phe Asn Leu Ser Glu Asp 515 520 525 Tyr Ile Ala His Lys Ile Ala His Ala Val Ala Gly Cys Ala Ser Ala 530 535 540 Val Ala Asn Lys Gly Lys Cys Arg Asp Gly Ala Ile Gly Ala Ala Val 545 550 555 560 Gly Glu Met Val Gly Glu Thr Leu Leu Asp Gly Arg Asp Val Gly Lys 565 570 575 Leu Ser Pro Gln Glu Arg Gln Lys Val Ile Ala Tyr Ser Gln Ile Ile 580 585 590 Ala Gly Ser Ala Val Ala Leu Val Lys Gly Asp Val Asn Thr Ala Val 595 600 605 Asn Ala Ala Thr Val Ala Val Glu Asn Asn Ser Leu Leu Ala Arg Arg 610 615 620 Arg Val Asn Ile Arg Trp Thr Pro Arg Gln Glu Leu Glu His Glu Tyr 625 630 635 640 Ala Ile Leu Glu Ile Gln Ala Ile Thr Asn Gln Ile Arg Arg Leu Asp 645 650 655 Pro Lys Phe Asn Gly Ile Ala Ile Leu Arg Thr Pro Gly Glu Pro Trp 660 665 670 Thr Arg His Asp Val Gln Thr Tyr Arg Gln Tyr Tyr Asn Gln Leu Arg 675 680 685 Glu Ser Arg Gly Phe Ala Val Glu Pro Ile Tyr Arg Ile Arg Ile Asn 690 695 700 Asn Gly Asn Glu Phe Asn Arg Ile Met Ser Ser Lys Tyr Pro Tyr Asn 705 710 715 720 Glu Leu Tyr Val Ala Asn Pro Lys Ser Ala Thr Gly Tyr Phe Arg Val 725 730 735 Asp Ser Tyr Asp Pro Ala Thr Arg Glu Ile Ile Ser Arg Lys Phe Thr 740 745 750 Gln Phe Ser Gln Ile Gln Glu Ser Thr Gly Ile Gly Tyr Ile Lys Glu 755 760 765 Ala Val Arg Lys Tyr Ser Pro Gly Thr Val Ile Ser Asn Val Pro Ser 770 775 780 Thr Pro Thr Thr Ile Arg Gly Arg Lys Leu Glu Gly Lys Leu Ile Leu 785 790 795 800 Glu Val Pro Ala Gln Val Asn Pro Ile Pro Gln Ser Val Leu Arg Ala 805 810 815 Ala Gln Glu Glu Asn Val Ile Ile Arg Asp Thr Thr Gly Arg Ile Tyr 820 825 830 Lys 162 acides amin,s acide amin, single linear peptide Peptide 1..162 42 Met Lys Lys Asp Ile Phe Tyr Cys Glu Gln Trp Ser Tyr Gly Tyr Lys 1 5 10 15 Arg Leu His Lys Pro Phe Ser Glu Lys Gln Ala Glu Glu Lys His Leu 20 25 30 Lys Gly Glu Leu Tyr Thr Ala Val Ile Gly Ser Ala Thr Gln Pro Glu 35 40 45 Tyr Val Ile Thr Leu Arg Glu Glu Val Gly Phe Phe Ser Val Asn Phe 50 55 60 Phe Asp Lys Phe Gly Arg Asp Tyr Leu Thr His Gln Phe Gln Lys Tyr 65 70 75 80 Ser Asn Ser Asn Tyr Tyr Phe Leu Ser Met Ala Val Trp Arg Asp Tyr 85 90 95 Ile Thr Leu Glu Ser His Asp Leu Ala Glu Gly Tyr Thr Tyr Phe Phe 100 105 110 Asn Glu Asn Thr Asp Asp Cys Tyr Val Leu Lys Gln Asp Phe Ile Asn 115 120 125 Asn Glu Arg Tyr Glu Lys Thr Glu Leu Tyr Ser Gln Lys Asp Lys Val 130 135 140 Ile Leu Phe Pro Lys Phe Gly Glu Tyr Asp Leu Val Leu Asn Pro Asp 145 150 155 160 Ile Ile 90 acides amin,s acide amin, single linear peptide Peptide 1..90 43 Met Asn Lys Arg Met Lys Met Cys Pro Ala Cys Gln Gln Gly Tyr Leu 1 5 10 15 Tyr His Ser Lys Pro Lys Tyr Leu His Asp Glu Ile Ile Leu Cys Asp 20 25 30 Glu Cys Asp Ala Val Trp Leu Lys Gly Met Asn Ile Phe Tyr Gly Glu 35 40 45 Tyr Glu Lys Asp Phe Tyr Ser Tyr Val Pro Phe Met Glu Ser Gln Gly 50 55 60 Ile Thr Ser Glu Cys Ile Trp Glu Gly Asp Leu Phe Asp His Pro Tyr 65 70 75 80 Tyr Glu Asp Glu Asn Ser Asn Asp Met Asp 85 90 313 acides amin,s acide amin, single linear peptide Peptide 1..313 44 Met Ser Ala Thr Glu Ile Glu Lys Ala Lys Ala Lys Ile Thr Ala Tyr 1 5 10 15 Ser Lys Leu Val Ala Gly Thr Ala Ser Ala Val Val Gly Gly Asp Val 20 25 30 Asn Thr Ala Ala Asn Ala Ala Gln Ile Ala Val Glu Asn Asn Thr Leu 35 40 45 Tyr Pro Arg Cys Val Gly Ala Lys Cys Asp Glu Phe Gln Lys Glu Gln 50 55 60 Gln Lys Trp Ile Arg Glu Asn Pro Glu Glu Tyr Arg Glu Val Leu Leu 65 70 75 80 Phe Gln Thr Gly Phe Ile Pro Ile Ile Gly Asp Ile Gln Ser Phe Val 85 90 95 Gln Ala Gln Thr Ala Ala Asp His Leu Phe Ala Leu Leu Gly Val Val 100 105 110 Pro Gly Ile Gly Glu Ser Ile Gln Ala Tyr Lys Val Ala Lys Ala Ala 115 120 125 Lys Asn Leu Gln Gly Met Lys Lys Ala Leu Asp Lys Ala Ala Thr Val 130 135 140 Ala Thr Ala Gln Gly Tyr Val Ser Lys Thr Lys Ile Lys Ile Gly Gln 145 150 155 160 Thr Glu Leu Arg Val Thr Ala Ala Thr Asp Lys Gln Leu Leu Lys Ala 165 170 175 Ile Gly Glu Gly Arg Asp Thr Thr Gly Lys Met Thr Glu Gln Leu Phe 180 185 190 Asp Ser Leu Ala Lys Gln Asn Gly Phe Arg Val Leu Ser Gly Gly Lys 195 200 205 Tyr Gly Gly Asn Asn Gly Phe Asp His Val Trp Gln Ala Ala Asp Gly 210 215 220 Ser Val Val Leu Ile Val Glu Ser Lys Gln Ile Arg Asn Gly Thr Val 225 230 235 240 Gln Leu Asn Pro Asn Gly Ala Gly Gly Tyr Thr Gln Met Ser Glu Asp 245 250 255 Trp Ile Arg Gln Val Leu Asp Gln Leu Pro Asp Gly Ser Pro Ala Lys 260 265 270 Ala Ala Val Phe Lys Ala Asn Lys Asn Gly Thr Leu Lys Thr Ala Ile 275 280 285 Ala Gly Val Asp Arg Gln Thr Gly Lys Ala Val Ile Leu Pro Val Lys 290 295 300 Val Pro Ser Lys Thr Asn Ile Arg Arg 305 310 311 acides amin,s acide amin, single linear peptide Peptide 1..311 45 Met Gly His Asn Met Met Thr Thr Gln Lys Trp Tyr Glu His Ile Thr 1 5 10 15 Asn Val Ile Ile Gly Asn Thr Ala Asn Phe Asn Ser Gly Cys Leu Asp 20 25 30 Ser Ile Asp Tyr Val Asp Glu Arg Lys Gly Val Pro Leu Ala Ala Met 35 40 45 Gln His Ile Phe Met Asp Val Arg Ala Ala Ala Ser His Ala Tyr Leu 50 55 60 Phe Glu His Asp Leu Lys Lys Phe Lys Gln Tyr Ala Tyr Val Ala Gly 65 70 75 80 Lys Leu Gly Val Leu Leu Ser Val Asn Ser Thr Asp Pro Glu Pro Phe 85 90 95 Phe Phe Pro Cys Asp Met Leu Asn Ile Gln Asn Pro Met Phe Leu Met 100 105 110 Leu Met Ser Asp Ser Pro Gln Leu Arg Glu Phe Leu Val Arg Asn Ile 115 120 125 Asp Asn Ile Ala Asn Asp Thr Glu Ala Phe Ile Asn Arg Tyr Asp Leu 130 135 140 Asn Arg His Met Ile Tyr Asn Thr Leu Leu Met Val Glu Gly Lys Gln 145 150 155 160 Leu Asp Arg Leu Lys Gln Arg Ser Glu Lys Val Leu Ala His Pro Thr 165 170 175 Pro Ser Lys Trp Leu Gln Lys Arg Leu Tyr Asp Tyr Arg Phe Phe Leu 180 185 190 Ala Phe Ala Glu Gln Asp Ala Glu Ala Met Lys Ala Ala Leu Glu Pro 195 200 205 Leu Phe Asp Lys Lys Thr Ala Arg Met Ala Ala Lys Glu Thr Leu Ser 210 215 220 Tyr Phe Asp Phe Tyr Leu Gln Pro Gln Ile Val Thr Tyr Ala Lys Ile 225 230 235 240 Ala Ser Met His Gly Phe Asp Leu Gly Ile Asp Gln Glu Ile Ser Pro 245 250 255 Arg Asp Leu Ile Val Tyr Asp Pro Leu Pro Ala Asp Glu Tyr Gln Asp 260 265 270 Ile Phe Asp Phe Met Lys Gln Tyr Asp Leu Ser Tyr Pro Tyr Glu Tyr 275 280 285 Leu Gln Asp Trp Ile Asp Tyr Tyr Thr Phe Lys Thr Asp Lys Leu Val 290 295 300 Phe Gly Asn Ala Lys Arg Glu 305 310 21 base pairs nucleotide single linear DNA (genomic) 46 GCCACCGGTA CGGAAACTGA A 21 30 base pairs nucleotide single linear DNA (genomic) NO NO 47 CCTGAATTCA TGTCTATTCC ATTTTGAAGA 30 31 base pairs nucleotide single linear DNA (genomic) NO NO 48 CCGAGATCTT TAACCCTTTG GGCTTAAGCG A 31 29 base pairs nucleotide single linear DNA (genomic) NO NO 49 GGGAGATCTC CCGCTCGTGT TGTGCATTA 29 28 base pairs nucleotide single linear DNA (genomic) NO NO 50 AAGAGATCTG CAGCCAAGGC TCTCGAAA 28 26 base pairs nucleotide single linear DNA (genomic) NO NO 51 GGGAGATCTC AGGCTGCCGC CGTTGA 26 28 base pairs nucleotide single linear DNA (genomic) NO NO 52 GGGAGATCTC ACCCCAAGAA CGCCAAAA 28 31 base pairs nucleotide single linear DNA (genomic) NO NO 53 GGGAGATCTG AACGTATAGT AATCTATCCA A 31 12 base pairs nucleotide single linear DNA (genomic) NO NO 54 AGTGGCTCCT AG 12 24 base pairs nucleotide single linear DNA (genomic) NO NO 55 AGCACTCTCC AGCCTCTCAC CGAG 24 12 base pairs nucleotide single linear DNA (genomic) NO NO 56 AGTGGCTCTT AA 12 10 base pairs nucleotide single linear DNA (genomic) NO NO 57 AGTGGCTGGC 10 24 base pairs nucleotide single linear DNA (genomic) NO NO 58 AGCACTCTCC AGCCTCTCAC CGAC 24 12 base pairs nucleotide single linear DNA (genomic) NO NO 59 GTACTTGCCT AG 12 24 base pairs nucleotide single linear DNA (genomic) NO NO 60 ACCGACGTCG ACTATCCATG AACG 24 12 base pairs nucleotide single linear DNA (genomic) NO NO 61 GTACTTGCTT AA 12 10 base pairs nucleotide single linear DNA (genomic) NO NO 62 GTACTTGGGC 10 24 base pairs nucleotide single linear DNA (genomic) NO NO 63 ACCGACGTCG ACTATCCATG AACC 24 12 base pairs nucleotide single linear DNA (genomic) NO NO 64 AATTCTCCCT CG 12 24 base pairs nucleotide single linear DNA (genomic) NO NO 65 AGGCAACTGT GCTATCCGAG GGAG 24 140 base pairs nucleotide single linear DNA (genomic) NO NO 66 GATCAACTTT TCCCTGTTTG TCCCATTACC GGTTTGAATG AACCGATTGC GCGCCGCGCG 60 TGTTGTTGGA CATTACCTGC GATTCAGACG GTACGATTGA CCACTACATC GAGGAGAACG 120 GCAATCAGGG TACAATGCTA 140 192 base pairs nucleotide single linear DNA (genomic) NO NO 67 GATCCGCGTA CTTGGTTTTT CATATTTTGC ATAGTCTTGT CGGTCGGGCA TCTTCCCCGA 60 CATCATCTAA ATTTGTCTTT ATTGGTTTTT ACGCCACTCA TTGCGGATAA ACAATATTCC 120 GCCTTGCCGT CGCGAATGTT CAAGCTAGCC TGCATCACCG TAATCAGGTT GCCCGTTACC 180 GAGCCTTCGA GA 192 188 base pairs nucleotide single linear DNA (genomic) NO NO 68 GATCCGGCTG CCCGACGCGC GCAAAATTGC CGCCGAGGAA AGCGCGCACA ACCACGACGG 60 CAAAACCAGC GTATGGCAAT ACAAACATCT CGTGTTCGGT ACGGCAGGCA TTTTCTGCTA 120 TGTCGGCGCG GAGGTGTCTA TCGGTTCGTT GATGGTCAAC GTATTGGGTT ATCTGAAAGG 180 GCTGGATC 188 304 base pairs nucleotide single linear DNA (genomic) NO NO 69 GATCCCCCAC TTTACCTCGG GCAGATTTTG CGCGTTCATT ACAATAGCGT ATTTATGCGT 60 TTGCGTTTGC GCTTGCCGCT GCCCCCCCCC CGCCGGTATG GGAAAACATC AATATGGCGG 120 TATAAAGCGC GGTATGGCGG AAAACCTGCC GTTTCCAAGT TTTATTCATC TTTTATTCCT 180 TGAGTTTGCC TTCACGGGAC GGGGCGGCGC GCGGAACGCG GGGTTCGGTA AACCGCCCGA 240 TTCCGCGCCC GCCGAATTGC TGATTGAAAA GCTTACTTCC CCATTTTAAC TTTGCACACT 300 GATC 304 243 base pairs nucleotide single linear DNA (genomic) NO NO 70 GATCAGACCC ATTTTCAGCG CACCGTAAGC GCGGATTTTC TCGAATTTTT CCAAAGCTGC 60 GGCATCGTTG TTGATGTCGT CTTGCAACTC TTTGCCCGTG TAGCCCAAGT CGGCGGCATT 120 CAGGAAAACG GTCGGAATGC CCGCGTTGAT GAGCGTGGCT TTCAAACGGC CTATATTCGG 180 CACATCAATT TCATCGACCA AATTGCCGGT TGGGAACATA CTGCCTTCGC CGTCGGCTGG 240 ATC 243 236 base pairs nucleotide single linear DNA (genomic) NO NO 71 CGGCGGCGTA GTCCGCCGCG ACAGCGTTAC CATAAGCGGG ACAGACTACA CCCCTTTATC 60 TAACCCGCAA AGTTTGGATA CGGAATTAAA ATGGTTGCTT CAAGAAGCTC CCGAAATAGA 120 AAATCCTTTC GACCGCGCCG TTTATCTCCA TAATAATTTG GCGTATCTTC AATATTTTAA 180 AGATTGCAAT AAACGTACTG CCAGAAACTG CATGACCTTG TCGCTGATGC GCTCCG 236 280 base pairs nucleotide single linear DNA (genomic) NO NO 72 CGGTCAATCA CAAGAAAGTC AGCCGTCTGA TGGCGAAGAC GGGGCTGAAG GCAGTGATAT 60 GGCGGCGCAA ATACCGCTCG TTCAAAGGAG AAGTCGGCAA AATTGCGCCG AATATCCTGC 120 GACGCTGTTT CCATGCAGAA AAGCCGAATG AGAAATGGGT AACGGACGTT GCCGAGTTCA 180 ATGTAGGCGG AGAAAAGATA TACCTTTCTC CGATTATGGA TTTGTTTAAC GGGGAAATCG 240 TCAGTTACCG TATTCAGACC CGCCCGACTT TCGATTTGGC 280 120 base pairs nucleotide single linear DNA (genomic) NO NO 73 CGGTCAGAAA CAGGCAAGGT AATGAAAATG CCTGAGGCAC GGACTGTGCT GCGAACGAAA 60 ACTCCTTACC GAAGTCTTCT ATACCCAGGC TCAATAGCCG CTCAAGGAGA GAGCTATCAT 120 120 base pairs nucleotide single linear DNA (genomic) NO NO 74 CGGTCAGAAA CAGGCAAGGT AATGAAAATG CCTGAGGCAC GGACTGTGCT GCGAACGAAA 60 ACTCCTTACC GAAGTCTTCT ATACCCAGGC TCAATAGCCG CTCAAGGAGA GAGCTATCAT 120 152 base pairs nucleotide single linear DNA (genomic) NO NO 75 CGGTGTTTTT CTTAACAATT CGCCGACTTC ATGGCGATAT TTAAGTGACA GTTGCTCCGC 60 CCACGCAGTT GCGCCGAACT CAGCACCACG ACATTATACT GATTATGCAC ATCGGCAAGA 120 TCAAACTGAC CTATCGTAGT ATCGCAGACT GT 152 381 base pairs nucleotide single linear DNA (genomic) NO NO 76 CGGGAGGTTT TGTGCATCCT GATACCGATC GGTTGTTGTT GCTCAAAGGA CAGAAGGCCG 60 CTGATAAACG AGATTACCTG TTTGTCGCTA TTGACGATTT TTATACTCTG CCATTTTGCC 120 AGACAAAACC GCAGACAGTG CTGCCAAGTT TCTGACCGAA CATCTGGCCG ACCCCTGCTT 180 GTACCTGATT GAGTACGCTT ACTCTGACAA TGATAGGTAA TATAAAGAGC CGTCCAACAT 240 GCTTTCGGTG CAGTTTGTTA TGATAATGGG ATTGGTTGGA GGCTTGCCCG ATTTGCTTGT 300 CCGCAGACCA ACGGTAAGGC GGAGCGGGTT ATCCGTACCT TGATGGAGAT GTGGCATGAG 360 GAACAGTCGT TTGACAGACC G 381 269 base pairs nucleotide single linear DNA (genomic) NO NO 77 CGGAGCATAA AATCGTTATT AAAGATAATG GTATAGGAAC GAGCTTCGAT GAAATCAATG 60 ATTTTTATTT GAGAATCGGT CGGAACAGAA GGGAAGAAAA ACAAGCCTCC CCGTGCGGAA 120 GAATTCCAAC GGGTAAAAAA GGCCTTGGTA AATTGGCATT ATTCGGGCTT GGCAACAAAA 180 TTGAAATTTC TACTATCCAG GGAAACGAAA GGGTTACTTT TACTTTGGAT TATGCAGAGA 240 TTCGAAGAAG CAAGGGTATT TATCAACCG 269 203 base pairs nucleotide single linear DNA (genomic) NO NO 78 CGGATGAAAA CGGCATACGC GCCAAAGTAT TTACGAACAT CAAAGGCTTG AAGATACCGC 60 ACACCTACAT AGAAACGGAC GCGAAAAAGC TGCCGAAATC GACAGATGAG CAGCTTTCGG 120 CGCATGATAT GTACGAATGG ATAAAGAAGC CCGAAAATAT CGGGTCTATT GTCATTGTAG 180 ATGAAGCTCA AGACGTATGG CCG 203 229 base pairs nucleotide single linear DNA (genomic) NO NO 79 CGGTTTCAGG TTGTCGCGAA GGCTCGGTAA CGGGCAACCT GATTACGGGT GATGCAGGCA 60 GCTTGAACAT TCGCGACGGC AAGGCGGAAT ATGTTTATCC GCAATGAGTG GCGTAAAAAC 120 CAATAAAGAC AAATTTAGAT GATGTCGGGG AAGATGCCCG ACCGACAAGA CTATGCAAAA 180 TATGAAAAAC CAAGTACGCG GATCAGGCAT GGATGCACGA TCCAATCCG 229 207 base pairs nucleotide single linear DNA (genomic) NO NO 80 CGGGTCGCTT TATTTTGTGC AGGCATTATT TTTCATTTTT GGCTTGACAG TTTGGAAATA 60 TTGTGTATCG GGGGGGGGTA TTTGCTGACG TAAAAAACTA TAAACGCCGC GCAAAATATG 120 GCTGACTATA TTATTGACTT TGATTTTGTC CTGCGCGGTG ATGGATAAAA TCGCCAGCGA 180 TAAAGAATTT GCGAGAACCT GATGCCG 207 224 base pairs nucleotide single linear DNA (genomic) NO NO 81 CGGCAACGAT TTGAGCTATC GCGGTTACGA CATTCTGGAT TTGGCACAAA AATGCGAGTT 60 TGAAGAAGTC GCCCACCTGC TGATTCACGG CCATCTGCCC AACAAATTCG AGCTGGCCGC 120 TTATAAAACC AAGCTCAAAT CCATGCGCGG CCTGCCTATC CGTGTGATTA AAGTTTTGGA 180 AAGCCTGCCT GCACATACCC ATCCGATGGA CGTAATGCGT ACCG 224 212 base pairs nucleotide single linear DNA (genomic) NO NO 82 CGGGAACAGC CATTGCCCAC GCCCACGCCC CCCAAGAAAG ACGGAAACTA CTGCCTAAAT 60 TTTCGGCAAT CAAGTTGACG ATTAAAGGGT TGGGGGCAGT TGCAGTAATA AACATAGCCG 120 ACGAAATGGG ATTGGAATGA TAGTTGACCA AAGCCAAATA TTTACCCATC TTGCCTTCTG 180 TGCCTTTTGC GGGATTGGAG CCGTAACTGC CG 212 353 base pairs nucleotide single linear DNA (genomic) NO NO 83 CGGGAATTCT GAGCAGAATG AAAGAAAGCA GGCTTGATAA TTTCATAAAG TTATTGGAAG 60 AAAAAGGATT TACCGTCCAT TTCGGTATTC ACAATACGGC TGATTACGGA ATTCCCCAAA 120 GCCGTAAAAG ATTTACGTTA ATTGCAAACA GAATAACCAA AGAAAAGCTG GAACCAGTCA 180 AGTATTCGGG CAAACGGCTT ACGGTAGCCG ATGTTTTGGG AATGGAAATG GCTTTCCCAA 240 CATTATTGCA GGACACCAAG ACGAAACGGA TTTTATGCAT AGCTGTGCGG GAATTATCTG 300 ATATCACTTG AACGATTGGC TTGATACCTA AAAACGGAGG AACCGTTGGC TTT 353 308 base pairs nucleotide single linear DNA (genomic) NO NO 84 AATTCCGTAT CCAAACTTTG CGGGTTAGAT AAAGGGGTGT AGTCTGTCCC GCTTATGGTA 60 ACGCTGTCGC GGCGGACTAC GCCCGGAGCC TTTTTCCAGT AAGTTTTCGG AAATCAGGCT 120 GTGGGTGGTT TTTAAGAAAT CCAACCAGTC AAACGGCTCG GGGCTGTCCA AACCGGACAC 180 AGGTGCCGGT AACTTTCCCT CAGGTTGATT AACATTACGG CATCCGAATA TAACTTCCCG 240 CCTGCGGTTT GCCCGAGTTT AAGCAATGCC TGCGTATCGT ATTGATTATA AAGTGTTTCC 300 TTCCAATT 308 104 base pairs nucleotide single linear DNA (genomic) NO NO 85 AATTCGTGTG CCGCGTCGAC AAACCGCTGA CGTAGCGGAT GTCTCATGCC ACGTTTCAAA 60 GCAGGTTGAT GGCGGTTAGC AACCCTCTGA TTTCACTGGG ATAT 104 89 base pairs nucleotide single linear DNA (genomic) NO NO 86 AATTGCGTAG AGTGGGCTTC AGCCACGTTT TTTCTTTTTC GGTCGTTGAT TGGTGGGCTG 60 AACCACTTGT TTCGGAAATC CGTATCATG 89 273 base pairs nucleotide single linear DNA (genomic) NO NO 87 AATTTCCACC TATGCCCTAC GCAGCGATTA TCCGTGGTTT ACCCAAAGGG TGATTATGGC 60 AAAAGCGCGG GGTTGAGCGA CCGCCTTTTG TTGCCGGCGT TCAAACGGGT TTTGATAGGA 120 AATGCAGGCA CGAAGCCTCG GCTGATTGTG ATGCACCTGA TGGGTTCGCA CAGTGATTTT 180 TGCACACGTT TGGATAAGGA TGCGCGGCGG TTTCAGTATC AAACTGAAAA AATATCCTGC 240 TATGTTTCCA TCAATCGCGC AAACCGATAA ATT 273 270 base pairs nucleotide single linear DNA (genomic) NO NO 88 AATTCTTCCG CACGGGGAGG CTTGTTTTTC TTCCCTTCTG TTCCGACCGA TTCTCAAATA 60 AAAATCATTG ATTTCATCGA AGTTCATTCC TATACCATTA TCTTTAATAA CGATTTTATG 120 CTCCGGTTTA TCGAATAACC TAACTTCCAC TTCCGTAGCA CATGCATCGT AGGCATTCGC 180 TATCAACTCG GCAATCGCAG GAACAGTGTG CGAATACAAT CTTTACACCC AAATGTTCGA 240 TTACGGTTGG CTCGAAACTC AATTTCAATT 270 267 base pairs nucleotide single linear DNA (genomic) NO NO 89 AATTATGAAC ACACGCATCA TCGTTTCGGC TGCGTTCGTT GCGTTGGCAT TAGCAGGTTG 60 CGGCTCAATC AATAATGTAA CCGTTTCCGA CCAGAAACTT CAGGAACGTG CCGCGTTTGC 120 CTTGGGCGTC ACCAATGCCG TAAAAATCAG CAACCGCAGC AATGAAGGCA TACGCATCAA 180 CTTTACCGCA ACTGTGGGTA AGCGCGTGAC CAATGCTATG TTACCAGTGT AATCAGCACA 240 ATCGGCGTTA CCACTTCCGA TGCAATT 267 234 base pairs nucleotide single linear DNA (genomic) NO NO 90 AATTTTTATT TGGTTCGTAG TCATTTTGTG CAACTGAACG ATATTCGTTT TCATCATTGC 60 TAACGTCTAG TGCCCATTGT GGCCCGTAAT AAGAGATTTC GTCTCCTTTT ACATGTTTGA 120 CGCTGACGGC ATACTGGGGA TCGATGACGG ATAATGTACG TCTGTTGACA TCTGCAACGC 180 TAAATCAATC ATCGGTATTG GATAATGCGT TGCCGATGTT TTGACTTGTA TGTT 234 295 base pairs nucleotide single linear DNA (genomic) NO NO 91 AATTCGGCCG GCTGTGTCAA ATAATGCGTT ACTTTGGCCG GGTCTTGTTC TTTGTAAGTG 60 GTGGTCTTTT TTTGCGCGTT ATCCCCATCT GTTTGAGTGC ATAGCAAATG GTGGCTGCCG 120 TACAATCAAA TGTTTGGCGT TCATGCAGAT AGGCATCATG GTGTTGCCCA ATATATTGAG 180 CCGGTTTTTG CCTATCCGAT TTGACGGCAT TTAGACCGGT AACTTGATGT TTTAAGCTGC 240 CTGTTTGTTT AAAGGCGAAT CCACAAGTAA AGCGTGTTTC TTGACAGGTT AAACG 295 259 base pairs nucleotide single linear DNA (genomic) NO NO 92 AATTGTGTAT ATCAAGTAGG ATGGGCATTT ATGCCTGACC TACAAAACCA AAAACAACCT 60 ACCACCCTTA ATCAACTCCA CAAACCCTCT TCAGACAACC TCGTTTTTTG AAAAACAATC 120 TGTAAACAGA TAACTGCTGA AGAATACCGT TGCCGAGCCC CAAAACCCGT ACTGCAACTT 180 TTATTGTGAA CTTCCCATTA TGAGAAAATC CCTTTTCGTC CTCTTTCTGT ATTCGTCCCT 240 ACTTACTGCC AGCGAAATT 259 379 base pairs nucleotide single linear DNA (genomic) NO NO 93 AATTGCACCA CGCGATGATG GGTACGCCTC TGTTGCCATT GCGACCGCCG CCGCCGTGCC 60 CGGTACGCTG GTCAACCTTG CCGCGGCGGA ACGGGTAAAG AAGTGCGCTT CGGGCATCCT 120 TCCGGTACAT TGCGCGTCGG TGCAGCGCCG AATGTCAGGA CGGACAATGG ACGGCCACCA 180 AAGCGGTTAT GAGCCGCAGC GCACGCGTGA TGATGGAAGG TTGGGTCAGG GTGCCGGAAG 240 ATTGTTTTTA AATTGGACGG CGAACCGGTC TATTCGTATT GGCGTTATAC CGCCGCAAAG 300 GCAGACCTTG AAACTGGTGC GTGCCGTGCA GGGCATGTAC GGCTATGTGT GCGTGGCGGG 360 CGGATTTGAT GTGCGGAAT 379 308 base pairs nucleotide single linear DNA (genomic) NO NO 94 AATTTGTTGG GCAGATGGCC GTGAATCAGC AGGTGGGCGA CTTCTTCAAA CTCGCATTTT 60 TGTGCCAAAT CCAGAATGTC GTAACCGCGA TACGTCAAAT CGTTGCCGGT ACGCAACGGT 120 ACACAAAGCG GTATTACCGG CCGCAACGCC AGAAAGCGCA ACGGATTTTT AGGTTTGAGG 180 GTCGGGGTTT GAGTAGTTTC AGTCATGGTA TTTCTCCTTT GTGTTTTTAT GGGTTTCGGG 240 TTTTCAGACG ACCGATGCGG ATTTGTTGAA AGGCAGTCTG AAAGCGGTAA ATCATTTTTG 300 AAACAATT 308 286 base pairs nucleotide single linear DNA (genomic) NO NO 95 AATTCGGAGG AGCAGTACCG CCAAGCGTTG CTCGCCTATT CCGGCGGTGA TAAAACAGAC 60 GAGGGTATCC GCCTGATGCA ACAGAGCGAT TACGGCAACT TGTCCTACCA CATCCGTAAT 120 AAAAACATGC TTTTCATTTT TTCGGCAAGC AATGACGCAC AAGCTCAGCC CAACACAACT 180 GACCCTATTG CCATTTTATG AAAAAGACGC TCAAAAAGGC ATTATCACAG TTGCAGGCGT 240 AGACCGCAGT GGAGAAAAGT TCAATGGCTC CAACCATTGC GGAATT 286 238 base pairs nucleotide single linear DNA (genomic) NO NO 96 AATTTGGATA CGTTGGAAAA GGGATATTTG ATTGGGAATG GGATGAAGAT AAGCGTAGAT 60 GAGTTGGGGA AAAAAGTGTT AGAACATATC GGTAAGAATG AACCGTTATT GTTGAAAAAT 120 CTACTGGTTA ACTTCAATCA GGGAAAACAT GAAGAAGTTA GGAAGTTGAT TTATCAGTTG 180 ATAGAGTTAG ATTTTCTGGA ACTTTTGTGA GGGATTCTAT GAAAAACTGG AAGCAATT 238 322 base pairs nucleotide single linear DNA (genomic) NO NO 97 AATTCGGCAC GCAGGTTTTC TAAAAAAAGG CCGTTGATGA CTTTGTCGAT ATTGGCGGCT 60 TCGGTGTAGT GCGCGCCCGC TTCGGCCGCT CTTGCGCGTC CATGACGGAT TGGAAGAGCG 120 TGCCGAAGAT TTCTGGACTG ATGTTGCGCC AGTCGAAATT GCCGACACGG GAGGAATACC 180 TGCCAACAAG AGTGCAGGCA GCGTAATCAA ACCACCCCCA CCCGCAATCG CATCGATAAA 240 TCCGGCAATC ATCGCAACCA AACCCAAAGC GAGTATTATG TATAAATCTT CCATGTTTCT 300 TAATCCTGTT AACTTGCACC AA 322 316 base pairs nucleotide single linear DNA (genomic) NO NO 98 AATTTGTCGG CAATCTTCCC GGGTCGCTTT ATTTTGTGCA GGCATTATTT TTCATTTTTG 60 GCTTGACAGT TTGGAGATAT TGTGTATCGG GGGGGGGTAT TTGCTGACGT AAAAAACTAT 120 AAACGCCGCA GCAAAATATG GCTGACTATA TTATTGACTT TGATTTTGTC CTGCGCGGTG 180 ATGGATAAAA TCGCCAGCGA TAAAGATTTG CGAGAACCTG ATGCCGGCCT GTTGTTGAAT 240 ATTTTCGACC TGTAATTACG ATTTGGCTTC CGCGCCGGCA CAATATGCCG CCAAGCGGCG 300 CCCACATTTT GGAAGC 316 217 base pairs nucleotide single linear DNA (genomic) NO NO 99 AATTCGGACA GTATGAATAC AGCGGATTAA TACAAGGTAA GTTCATTACA ACGGAAAAAC 60 CTTTAAAGAA TAATATGAAA GGTATTACCT TGTTTGCCAA CGGGAATGGT AAATATGCCC 120 GAGTTTTTCA CTGAATAGCG AATCCAGCCA TTTCTATTCA TATTTGACTG GATGGCTGAA 180 TGTGGACTTT ATAGATAATG ACGATGAAGA TTTAATT 217 

1/ DNAs, characterized in that they are in all or part genes, with their reading frame, present in Neisseria meningitidis (called Nm below), but absent both from Neisseria gonorrhoeae (called Ng below) and from Neisseria Pactamica [sic] (called Nl below), with the exception of genes involved in the biosynthesis of the polysaccharide capsule, frpA, frpC, opc, porA, rotamase, the sequence IC1106 [sic], IgA proteases, pilin, pilC, proteins which bind transferrin and opacity proteins. 2/ DNAs according to claim 1, characterized in that they are present in Nm, but absent from Ng. 3/ DNAs according to claim 2, characterized in that they comprise one or more sequence(s) present on the chromosome of Nm Z2491 between tufA and pilT, or region 1 of the chromosome, and/or the nucleotide sequence(s) capable of hybridizing with the said sequence(s). 4/ DNAs according to claim 2, characterized in that they comprise one or more sequence(s) present on the chromosome of Nm Z2491 between pilQ and λ740, or region 2 of the chromosome, and/or the nucleotide sequence(s) capable of hybridizing with the said sequence(s). 5/ DNAs according to claim 2, characterized in that they comprise one or more sequence(s) present on the chromosome of Nm Z2491 between argF and opaB, or region 3 of the chromosome, and/or the nucleotide sequence(s) capable of hybridizing with the said sequence(s). 6/ DNAs according to claim 3, characterized in that their sequence corresponds in all or part to SEQ ID No. 9, 13, 22 or 30, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or is capable of hybridizing with at least a fragment of any one of these sequences. 7/ DNAs according to claim 4, characterized in that their sequence corresponds in all or part to SEQ ID No. 1, 2, 4, 6, 7, 10, 15, 31 or 34, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or is capable of hybridizing with at least a fragment of any one of these sequences. 8/ DNAs according to claim 4, characterized in that they are all or part of the DNA sequence SEQ ID No. 36 or sequences corresponding to the open reading frames SEQ ID No. 37, SEQ ID No. 38, SEQ ID No. 39, SEQ ID No. 40, SEQ ID No. 41, SEQ ID No. 42, SEQ ID No. 43, SEQ ID No. 44, SEQ ID No. 45 and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or is [sic] capable of hybridizing with at least a fragment of any one of these sequences. 9/ DNAs according to claim 5, characterized in that their sequence corresponds in all or part to SEQ ID No. 8, 21, 23, 25, 26, 28, 29, 32 or 35, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or is capable of hybridizing with at least a fragment of any one of these sequences. 10/ DNAs according to claim 2, characterized in that their sequence corresponds in all or part to SEQ ID No. 3, 5, 11, 12, 14, 16, 18, 19, 20, 24, 27 or 33, and/or to any sequence located at more or less 20 kb from these SEQ ID on the chromosome of an Nm strain, and/or is capable of hybridizing with at least a fragment of any one of these sequences. 11/ DNAs according to claim 1, characterized in that they are common with those of Ng, but are absent from Nl. 12/ DNAs according to claim 11, characterized in that they comprise one or more sequence(s) present on the chromosome of Nm Z2491 between arg J and reg F, or region 4 of the chromosome, and/or the nucleotide sequence(s) capable of hybridizing with the said sequence(s). 13/ DNAs according to claim 11, characterized in that they comprise one or more sequence(s) present on the chromosome of Nm Z2491 between the marker lambda 375 to pen A, or region 5 of the chromosome, and/or the nucleotide sequence(s) capable of hybridizing with the said sequence(s). 14/ DNA according to any one of the preceding claims, characterized in that it codes for a protein exported beyond the cytoplasmic membrane. 15/ DNAs according to any only of claims 1 to 14, characterized in that all or part of their sequence corresponds to a region conserved within the Nm species. 16/ DNA according to any one of claims 1 to 15, characterized in that it is inserted in a transfer or expression vector, such as a cosmid, plasmid or bacteriophage. 17/ Host cell, more particularly bacterial cell or Nm cell, transformed by insertion of at least one DNA according to any one of claims 1 to
 15. 18/ Cell comprising genes or gene fragments specific to Nm, more particularly bacterial cell or Nm cell, the chromosome of which is deleted by at least one DNA according to any one of claims 1 to 15, in particular a DNA responsible for the pathogenicity. 19/ DNAs, characterized in that their sequence corresponds in all or part to the transcription of at least one DNA sequence or sequence fragment according to any one of claims 1 to
 15. 20/ Antisense nucleic acids, characterized in that their sequence corresponds to the antisense of at least one nucleotide sequence according to any one of claims 1 to 15 or 19, or a fragment of such a sequence, and in that they carry, where appropriate, at least one chemical substituent, such as a methyl group and/or a glycosyl group. 21/ Polypeptides, characterized in that they have an amino acid chain corresponding to all or part of a sequence coded by the nucleic acids defined in any one of claims 1 to 15 or 19, or deduced from sequences of these nucleic acids, with, where appropriate, modifications with respect to the coded or deduced sequences, where these modifications do not alter the biochemical properties observed in the natural polypeptide. 22/ Peptides according to claim 21, characterized in that they are peptides exported beyond the cytoplasmic membrane, more specifically peptides corresponding to all or part of those coded by a DNA according to claim
 14. 23/ Antibodies, characterized in that they are polyclonal or monoclonal antibodies directed against at least one epitope of a peptide according to claim 20 or 21, or fragments of these antibodies, more particularly fragments Fv, Fab, Fab′2, or also anti-antibodies capable of recognizing, by a reaction of the antigen-antibody type, the said antibodies or their fragments. 24/ Process for obtaining Neisseria meningitidis-specific DNA banks, comprising mixing of two DNA populations, realization of at least one subtractive hybridization-amplification iteration, and collection of the desired DNA or DNAs, followed, where appropriate, by its/their purification with elimination of redundant sequences. 25/ Process according to claim 24, characterized in that, to obtain a bank which is specific to Nm, in contrast to Ng two DNA populations originating respectively from a strain of Neisseria meningitidis, or a reference strain, for which the specific bank is to be constructed, and a strain of Neisseria gonorrhoeae, or a subtraction strain, the DNA sequences of these strains being those obtained by random shearing of the chromosomal DNA of the subtraction strain, in particular by repeated passage through a syringe, and cleavage of the chromosomal DNA of the reference strain, preferably by a restriction enzyme producing fragments less than about 1 kb in size, and in that to obtain a bank of DNAs common between Nm and Ng, but specific with respect to Nl, three different banks are constructed, two of them by digestion of the chromosomal DNA of Nm by MboI and Tsp5091, and the third by digestion of the chromosomal DNA of Nm with MspI, two subtraction series are carried out, and the DNAs having the required specificity are collected. 26/ Banks of DNA clones obtained by carrying out the process according to claim 24 or
 25. 27/ Use of the process according to claim 24 to obtain banks of DNAs specific to a given cell or to a given variant of the same species of cell, where another species or another variant which is close genomically and expresses different pathogenic potencies exists, in particular banks of DNAs specific to cryptococci, Haemophilus, pneumococci or also Escherichia. 28/ Method for diagnosis of a meningococcal infection, and more particularly of meningococcal meningitis, by demonstration of the presence of Neisseria meningitis in a biological sample, characterized in that it comprises the stages of: bringing into contact a biological sample to be analysed and a reagent formulated from at least one nucleic acid as defined in one of claims 1 to 15 or 19, if appropriate in the form of a nucleotide probe or a primer, or, as a variant, from at least one antibody or a fragment of an antibody, as defined in claim 23, under conditions which allow respectively hybridization or a reaction of the antigen-antibody type, and detection of any reaction product formed. 29/ Method for diagnosis of an immune reaction specific to meningococcal infection, characterized in that it comprises the stages of: bringing into contact a biological sample to be analysed and at least one polypeptide according to any one of claim 21 or 22 or an anti-antibody according to claim 23, or a fragment thereof, these products being labelled, where appropriate, under conditions which allow a reaction of the antigen-antibody type to be effected, and detection of any reaction product formed. 30/ Kits for carrying out a method according to any one of claim 28 or 29, characterized in that they comprise at least one reagent as defined in claim 28 or 29, that is to say of the nucleic acid, antibody or peptide type, products, in particular markers or buffers, which enable the intended nucleotide hybridization reaction or immunological reaction to be carried out, as well as use instructions. 31/ Vaccine composition including in its spectrum, in particular in combination with at least one childhood vaccine, antimeningococcal prophylaxis and intended for prevention of any form of infection by Neisseria meningitidis, characterized in that it comprises, in combination with (a) physiologically acceptable vehicle(s), an effective amount: of peptide according to claim 21 or 22, or of antibody or anti-antibody fragment according to claim 23, this material optionally being conjugated, in order to reinforce its immunogenicity, with a carrier molecule such as a poliovirus protein, tetanus toxin, protein produced by the hypervariable region of a pilin. 32/ Vaccine composition including in its spectrum, in particular in combination with at least one childhood vaccine, antimeningococcal prophylaxis and intended for prevention of any form of infection by Neisseria meningitidis, characterized in that it comprises, in combination with (a) physiologically acceptable vehicle(s), an effective amount: of nucleic acids according to any one of claims 1 to 15 or 19 or of cells according to claim 17 or
 18. 